University of Windsor

Scholarship at UWindsor
Electronic Theses and Dissertations

Theses, Dissertations, and Major Papers

2012

Expression of miRNA in different regions of the colon: An
investigation in Zucker(fa/fa) rats
Vaishali Basu
University of Windsor

Follow this and additional works at: https://scholar.uwindsor.ca/etd

Recommended Citation
Basu, Vaishali, "Expression of miRNA in different regions of the colon: An investigation in Zucker(fa/fa)
rats" (2012). Electronic Theses and Dissertations. 63.
https://scholar.uwindsor.ca/etd/63

This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor
students from 1954 forward. These documents are made available for personal study and research purposes only,
in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution,
Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder
(original author), cannot be used for any commercial purposes, and may not be altered. Any other use would
require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or
thesis from this database. For additional inquiries, please contact the repository administrator via email
(scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208.

Expression of miRNA in different regions of the colon: An investigation in Zucker(fa/fa)
rats

by

Vaishali Basu

A Thesis
Submitted to the Faculty of Graduate Studies
through Biological Sciences
in Partial Fulfillment of the Requirements for
the Degree of Master of Science at the
University of Windsor

Windsor, Ontario, Canada

2011

© 2011 Vaisahli Basu

Expression of miRNA in different regions of the colon: An investigation in Zucker(fa/fa)
rats

by

Vaishali Basu

APPROVED BY:

______________________________________________
Dr. Siyaram Pandey
Department of Chemistry and Biochemistry

______________________________________________
Dr. Melania Cristescu
Department of Biological Sciences

______________________________________________
Dr. Ranjana Bird, Advisor
Department of Biological Sciences

______________________________________________
Dr. John Hudson, Chair of Defense
Department of Biological Sciences

September 09, 2011

DECLARATION OF ORIGINALITY

I hereby certify that I am the sole author of this thesis and that no part of this thesis has
been published or submitted for publication.
I certify that, to the best of my knowledge, my thesis does not infringe upon anyone’s
copyright nor violate any proprietary rights and that any ideas, techniques, quotations, or
any other material from the work of other people included in my thesis, published or
otherwise, are fully acknowledged in accordance with the standard referencing practices.
Furthermore, to the extent that I have included copyrighted material that surpasses the
bounds of fair dealing within the meaning of the Canada Copyright Act, I certify that I
have obtained a written permission from the copyright owner(s) to include such
material(s) in my thesis and have included copies of such copyright clearances to my
appendix.
I declare that this is a true copy of my thesis, including any final revisions, as approved
by my thesis committee and the Graduate Studies office, and that this thesis has not been
submitted for a higher degree to any other University or Institution.

iii

ABSTRACT

The role of obesity in regulation of microRNA (miRNA) expression in distal and
proximal colon was assessed: 1) isolation and quantification methods for miRNAs were
established in rat liver tissue; 2) miRNA expression patterns were compared using
miRNA PCR arrays in lean proximal and distal colonic tissue; and 3) the influence of
obesity on miRNA expression in these colonic regions was investigated by screening
cancer miRNA coding genes in colonic mucosal samples from Zucker obese and lean
rats. Up-regulation of 20 miRNAs was observed in obese liver tissue. Colonic mucosal
miRNA expression patterns and abundance differed for distal and proximal colonic
regions in both lean and obese tissue. Obesity exerted a profound region-specific effect
on miRNA expression patterns and levels indicating biologically distinct tissue in distal
and proximal colon. Obesity markedly affects miRNA gene regulation, and miRNA is a
key molecular player in the genesis of colon cancer.
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CHAPTER1
INTRODUCTION

Overview
Development of colon cancer is a complex multistep process involving sequential
clonal selection and propagation of transformed cells. It is recognized that there are
multiple players which orchestrate the important events in the life of a transformed
cells. These players include host’s physiological state and interaction of the
transformed cells with the normal surrounding cells of the host organ as well other
organ systems. The complex orchestrated events allow the transformed cells to either
complete their life cycle and emerge as tumor or lead to premature death.
It is recognized now that the term “colon cancer” is normally used to represent
multiple cancer sub-types based on the mutational spectra of the cancers and their
morphology. Ample evidence exist to support the concept that colon is not a single
organ and that proximal (right sided colon) and distal colon (left sided colon) are
embryologically and physiologically different. Subsequently, the tumors appearing in
these regions are also biologically different. A majority of these evidences are from
epidemiological and clinical studies. A limited exploration has been conducted in
animal models.
Our ability to dissect the process of colon carcinogenesis at the molecular level has
added a number of new molecular players, miRNA being prominent among them.
miRNAs or miRNAs are known as the master regulators of genes involved in normal
functioning of the cell as well as pathogenesis of cancer. Hence the study of their
functioning and regulation in normal versus tumor cell is important for identification
of new molecular targets in cancer preventive therapies.
Obesity is linked to heightened risk of colon cancer. In our laboratory we have used
the Zucker obese (Zk-Ob) rats as a model to study the link between obesity,
metabolic syndrome-X and colon cancer. In this model, tumors mainly appear in the
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distal colonic regions however, a number of tumors also appear in the proximal
colonic regions. Now it is known that several miRNAs are associated with
inflammation

and

associated

diseases

like

colitis,

rheumatoid

arthritis,

atherosclerosis, allergic airway inflammation. In our laboratory, we are interested to
develop animal model of carcinogenesis focusing on the biology of the tumors. The
purpose of this research was to establish the method of miRNA isolation and to
quantify their expression levels in rat colon under obese conditions. We used the
Zucker obese (Fa/fa) and lean (fa/fa) rats as model system.

Hypothesis
The hypothesis which provides the basis of this dissertation is that obese state will
influence the composition and expression levels of miRNAs in the colons of Zucker rats.
During this investigation it was of interest to further determine if obesity known to
heighten the risk of colon cancer will influence miRNA expression in distal versus
proximal colon. This hypothesis is based on the fact that the clinical tumor samples from
proximal colon exhibit different mutational spectra than those from distal colon. We have
recently published that in Zucker obese rats, the molecular feature of the tumors
appearing in proximal colon also differ from those that appear in the distal regions. We
speculated that the ability of proximal and distal colonic regions to respond to DNA
damage and repairs as well as sustain the growth of transformed cells with specific
mutations depends on the biology of the host tissue.
Specific aims of research
Aim 1: To establish the method of isolation and quantification of miRNAs in rat
tissue (liver).
Aim 2: To determine if obesity influences miRNA expression level and pattern in
distal and proximal regions of the colon.
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To meet the specific aim 1 we used liver tissue from Zucker obese and lean rats. . To
meet the aims 2 we assessed the expression levels of miRNA in lean rats and compared
the expression pattern in the distal and proximal colonic regions. This study was followed
by the assessment of miRNAs in obese rat colonic tissues by the regions. To put this
dissertation in proper perspective a background information on colonic structure and
anatomical differences between the distal and proximal colonic regions, development of
colon cancer, link between obesity and colon cancer and role of miRNAs structure and
function are provided. For brevity the key information is provided with specific
references.
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CHAPTER 2
REVIEW OF LITERATURE

Colon
The large intestine or the colon is a muscular tubular organ about 1.5 meters in
length which represents the terminal part of the gastro-intestinal tract. The colon
consists of the caecum (with an attached appendix), ascending, transverse,
descending and sigmoid components ending with the rectum. Primary functions of
the colon involve processing of waste material, reabsorption of water and nutrients,
and mucous production.(Arthur F. Dalley 1999).

Histologically, the colon has four distinct layers: innermost mucosa, sub mucosa,
muscularis externa and outermost serosa. (Arthur F. Dalley 1999) (Figure1.1). The
innermost mucosal layer consists of invaginations known as crypts lined with colonic
epithelium. Unlike the small intestine, colonic crypts have no villi for nutrient
absorption. Crypts are supported by the lamina propria consisting of connective
tissue, blood vessels, and immune cells including lymphocytes and macrophages.
(Arthur F. Dalley 1999) The mucosal layer is the most common origin for colon
cancers.
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Figure 1.1 Structure of colon. The colon or the large intestine is a hollow, muscular
and tubular organ with four layers: the innermost mucosa, sub mucosa, muscularis
externa and outermost serosa. The innermost mucosal epithelium has invaginations
called ‘colonic crypts’ which are the site of origin of colon cancer. (adapted and
modified from Yi-Ben Chen, updated 2010)

Right and left side of colon
Embryologically, the colon develops partly from the midgut (ascending colon to
proximal transverse colon) and partly from the hind gut (distal transverse colon to
sigmoid colon). (Figure1.2) The ascending colon which lies vertically on the right
side of the splenic flexure, is also referred to as the ‘proximal’ colon. The transverse
colon again takes a right-angled turn just below the spleen (splenic flexure) and

5

becomes the descending (left) colon, which lies vertically in the most lateral left part
of the abdominal cavity.

Figure 1.2 Colon anatomy. Colon has been divided into three parts depending on its
location with respect to splenic flexure. On right side of the splenic flexure is the
ascending colon also known as ‘proximal’ colon and on the left side of the splenic
flexure is the descending colon also known as the ‘distal’ colon. Transverse colon
runs horizontal.

Colonic epithelium is a highly diverse and dynamic system involving constant cell
renewal. (Ding, Ko et al. 1998). Continuously proliferating stem cells situated at the
base are responsible for replenishing the entire epithelium every 3-8 days.(Cotran
R.S. 1999) This cell regeneration occurs within the basal two-third portion of the
crypt. As the cells migrate upwards they differentiate into specialized cell types
including absorptive, mucous secreting, endocrine, and anti-bacterial protein
secreting Paneth cells. (Radtke and Clevers 2005; Schneikert and Behrens 2007)
(Figure 1.3)
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Figure 1.3 Differentiation of colonic epithelium. The colonic epithelium has
invaginations called crypts which have a population of stem cells at the base that give rise
to actively dividing precursors. These precursor cells migrate to the top of the colon and
and differentiate as enterocytes (absorptive cells), entero endocrine (hormone secreting
cells), goblet cells (mucus secreting cells) and paneth cells (antimicrobial toxin secreting
cells) ( adapted and modified from Jean Schneikert, Jurgen Behrens, Gut 2007)

Colorectal Cancer
Colorectal cancer (CRC) is the 3rd most common malignancy and 4th most common
cause of cancer related mortality worldwide. (Tenesa and Dunlop 2009) It happens to
be the 2nd leading causes of cancer related deaths in the United States and other
developed countries, despite considerable advances in diagnosis and treatment
techniques.(Jemal, Murray et al. 2005; Jemal, Siegel et al. 2009). It alone accounts
for 11% of worldwide cancer cases, preceded only by prostate, lung and breast
cancer. In addition, it is estimated that 50% of the population will develop an
adenomatous polyp by the age of 70. (Jemal, Murray et al. 2005)
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Approximately, 20% of CRC cases have a familial basis, (Rustgi 2007) where some
are associated with well-defined syndromes, such as hereditary non polyposis
colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP). However,
majority of the CRC cases have been linked to environmental factors and food borne
mutagens, specifically intestinal microflora including pathogens and chronic
intestinal inflammation, which predisposes tumor formation.

CRC is multistep, multi factorial disease that involves the clonal selection and
clonal propagation of initiated colonic epithelial cells, which progress from normal
to precancerous to malignant states over a span of 5-40 years.(Harris 1991; Roncucci
L. 1991.; Lei Cheng 2003 December) . The sequential events of colon carcinogenesis
concerning genetic and phenotypical changes are very well characterized by the
adenoma-carcinoma model first described by Fearon and Vogelstein (1990).
According to this model, CRC is caused by accumulation of mutations in the
classical oncogenes and tumor suppressors genes, which correspond to a sequential
transition of single pre-neoplastic cell to aberrant crypt foci (ACF) and then to
adenoma and metastatic carcinoma. (Figure 1.4) The earliest molecular alteration in
this pathway is mutation in the adenomatous polyposis coli (APC) tumor suppressor
gene which is a component of the Wnt signaling pathway. This is followed by
mutation in the KRAS and TP53, in the larger adenomas and invasive carcinoma.
(Fearon and Vogelstein 1990) This pathway is referred to as the ‘APC pathway’ or
the ‘chromosomal instability (CIN) pathway’ because the colorectal tumors arising
by this pathway are characterized by gross chromosomes abnormalities including
deletions, insertions, and loss of heterozygosity. Another molecular pathway
proposed is the DNA mismatch repair pathway.(Aaltonen, Peltomaki et al. 1993) The
key element of this pathway is mutation in the DNA repair enzymes e.g MLH1,
MSH2, which results in accumulation of mutations in the microsatellite regions of
the genome. (H Iino 2000 July) This results in microsatellite instability in the tumors
arising from this pathway and hence it is also called microsatellite instability (MSI)
pathway.
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Figure 1.4 Fearon–Vogelstein model of colon carcinogenesis. The sequential events of
colon carcinogenesis concerning genetic and phenotypical changes are very well
characterized by the adenoma-carcinoma model first described by Fearon and Vogelstein
(1990)

Evidences indicating that adenomas might not be the only CRC precursor began to
emerge in 1990. Longacre and Fenoglio - Preiser studied a group of polyps that
showed mixed histology of both hyperplastic and adenomatous polyps.(Longacre TA
1990) These lesions had glands with serrated appearance and showed nuclear
features of adenomas, hence they were called serrated adenomas. The adenoma
carcinoma pathway for serrated polyps is different from the traditional CIN or MSI
pathway. For e.g- APC and TP53 mutations are rare, whereas alterations in
microsatellite sequence and hypermethylation of CpG islands are more common.
There are two overlapping pathways for development of serrated lesions. The first
one is more common in the right sided colon (proximal) and is characterized by high
9

level of MSI and CpG island methylation and BRAF mutation.(Spring, Zhao et al.
2006) The second one is more common in left sided colon (distal) and shows
microsatellite stability (MSS) or low grade of MSI (MSI-L) and also show mutations in
KRAS. (Jass, Whitehall et al. 2002)
Obesity associated inflammation and colon cancer
Obesity is a chronic inflammation state and a rising epidemic in North America, with
both environmental and genetic etiological factors.(Formiguera and Cantón 2004)
The connection between obesity and risk of colon cancer is well established and has
a great

deal

of supporting evidence from

genetic,

pharmacological

and

epidemiological data. (Rapp, Schroeder et al. 2005). While the biochemical and
molecular links between the two physiological disorders are still under review, the
interconnected roles of insulin resistance , adipose tissue and inflammation are well
documented in literature. (Figure 1.5) Key mediators of inflammation-induced cancer
include nuclear factor kappa B (NFκB), reactive oxygen and nitrogen species
(RONS), inflammatory cytokines, chemokines, adhesion molecules and specific
miRNAs. Chronic inflammation predisposes cells for oncogenic transformation by
inducing genomic instability, increasing cell proliferation and angiogenesis, altering
the genomic epigenetic state.
Physiological parameters linking obesity and cancer
Obesity or chronic inflammation state is often encountered with high levels of
glucose, triglycerides, cholesterol in the blood plasma due to inactivity of the insulin
hormone or its receptor. Insulin resistance implies a cells inability to respond to
normal levels of insulin, thus requiring abnormally high amounts of insulin hormone
for glucose metabolism. This condition further leads to irregular triglycerides, fatty
acids and glucose levels, all metabolic aberrations that also correlate with an
increased risk of colorectal cancer.(Gunter and Leitzmann 2006). There are
convincing evidences that suggest the connection between obesity and colon cancer
risk in three possible ways. (reviewed by Gunter and Leitzmann 2006) The first
being the fact that insulin hormone is a growth factor which is known to promote cell
10

growth and proliferation. Hence, the exposure of high levels of insulin to parts of the
body that are not accustomed to it e.g- colon, can interfere with the normal cell
signaling and promote cell proliferation. (Gunter and Leitzmann 2006) This has been
experimentally proved by Kiunga et al 2004, who reported the presence of high
levels of insulin and insulin receptor in colon tumor cells compared to normal
mucosa. Secondly, an insulin resistant state also promotes high levels of circulating
insulin-like growth factor (IGF), which can also promote colonocyte division and
block apoptosis by receptor binding. (Giovannucci 2001) Increased IGF-1-receptor
(IGF-IR) also stimulates cell division in intestinal epithelial cells (Ma J. 1999) and
several epidemiological studies have shown positive correlation between IGF and IGF-IR
levels and colon cancer risk.(Komninou, Ayonote et al. 2003) Finally, the high
circulating plasma glucose and

lipids associated with insulin resistance serve as a

reservoir for reactive oxygen species (ROS) generation, known contributors to
carcinogenesis. High visceral abdominal fat found in obese individuals is especially a
critical source for ROS. (Furukawa, Fujita et al. 2004; Frezza, Wachtel et al. 2006)
Along with oxidative stress, increased amount of fat tissue promotes a proinflammatory environment, also strongly correlates with increased cancer risk.
Cytokines/adipokines such as tumor necrosis factor-α (TNF-α) are readily secreted
by adipocytes and further enhance inflammation, insulin resistance, impaired glucose
metabolism and ROS production. (Furukawa, Fujita et al. 2004; Sonnenberg G.E.
2004.)
Leptin, which is also known as the hormone of satiety, has been implicated in obesity
associated colon cancer. Though its role is not very clear, it has been shown to
accelerate HT-29 cell proliferation and promote ACF formation in vivo.(Liu Z 2001.)
Interestingly, F344 rats administered with continuous high dose of leptin have shown
reduction in the number of ACF compared to controls. (Aparicio, Guilmeau et al.
2004) Leptin secreted from adipose tissue has also been shown to enhance insulin
resistance. (Matsuzawa 2006)
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Metabolic Syndrome X
Many of the physiological abnormalities associated with obesity or insulin resistance
are collectively referred to as Metabolic syndrome, or syndrome X. It is a term given
by Reavan in 1988, to the physiological disorders associated with obesity,
specifically abdominal/visceral obesity. Although there are contradicting views
regarding the inclusion of insulin resistance and dyslipidaemia (including
hypercholesterolemia and hypertriglycerolemia) in this syndrome, hyperglycemia
and hypotension have been unanimously included in this category.(Shaw, Hall et al.
2005; Sorrentino 2005). These symptoms or abnormalities have been associated with
diabetes, atherosclerosis and cancer.
Oncogenic mechanisms associated with inflammation
Prolonged inflammation can induce DNA mutations and contribute to genomic
instability in more than one ways. (Perwez Hussain and Harris 2007; Colotta,
Allavena et al. 2009) Free radicals (RONS), produced during inflammation can
reduce the expression and enzymatic activity of the critical DNA repair enzymes eg.
mut S homolog 2 and 6. It can further cause increased expression of DNA
methyltransferases that can cause global hypermethylation of the genome. The
downstream effect of this includes silencing of DNA mismatch repair enzymes (eghMLH1 and hSMH2) and several tumor suppressor genes (eg- APC, CDKN 2,
BRCA1,Rb and MDM2) by promoter methylation. (Fleisher, Esteller et al. 2000; Das
and Singal 2004)
Molecular mediators common to inflammation and cancer
Inflammation can induce cancer by both extrinsic and intrinsic pathways. In extrinsic
pathway, chronic inflammation itself is the driving force, whereas in intrinsic
pathway, the genetic alteration of oncogenes and tumor suppressors as well as
various inflammatory mediators play an important role in carcinogenesis. The
inflammatory mediators include the cytokines, chemokines RONS, COX-2 and
12

NFκB. For eg- a dominant mutation in Ras proto-oncogene, can induce inflammatory
response through induction of pro-inflammatory cytokines interleukins (ILs) IL1,
IL6 and IL11 and the chemokine IL8, which aid in Ras mediated oncogenesis. (Bos
1989) Ras also induces IL-8 that mediates tumorigenesis and angiogenesis.
(Sparmann and Bar-Sagi 2004) Genetic mutations stimulate the tumor cells to
produce inflammatory cytokines and free radicals, which creates a feedback loop
where the tumor cells recruit inflammatory cells that can produce additional
cytokines and free radicals to the site of tumor that can aid tumorigenesis. (Figure
1.5)
Some of the key players are described in detailed in the following sections:
Nuclear Factor Kappa B
Nuclear factor kappa B or NFκB as it is commonly called is a transcription factor
and key mediator of inflammation induced carcinogenesis. (Shen and Tergaonkar
2009) Under normal condition, NFκB is bound to its negative regulator also called
the inhibitor of kappa B (IκB) and stays inactive in the cytoplasm. Following an
inflammation stimulus, IκB kinase phosphorylates IκB and targets it for proteosomal
degradation. Activated NFκB translocates to the nucleus where it drives the
transcription of its target genes, many of which are inflammation related egcytokines and chemokines, nitric oxide synthase (NOS) , cyclooxygenase (Cox-2)
and tumor necrosis factor (TNF)α.(Naugler and Karin 2008)

NFκB creates a protumorigenic environment by turning on the expression of
following set of genes:
1.) Cell cycle related genes eg c-Jun-N-terminal kinase that increase cell
proliferation
2.) Vascular endothelial growth factor (VEGF) and angiopoetin that stimulate
angiogenesis
3.) Bcl2, Bcl-xL, and cFLIP that makes cell resistant to apoptosis and necrosis.
4.) Pro-inflammatory cytokines, chemokines and adhesion molecules.
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Inflammatory bowel disease (IBD) which is associated with colitis associated cancer
(CAC), show persistant activation of NFκB in the myeloid and epithelial cells of
colonic mucosa. (Rogler and Andus 1998; Chung 2000)

Reactive oxygen and nitrogen species (RONS)

These are highly reactive free radicals produced by inflammatory cells, collectively
known as the reactive oxygen and nitrogen species (RONS). They have the ability to
induce DNA strand breaks, mutations and aberrant cross linking, causing genomic
instability. Chronic inflammation results in elevated levels of RONS that causes
oxidative and nitrosative stress that contributes to tumorigenesis. (Hussain, Trivers et
al. 2004; Hofseth 2008) In colitis associated cancer (CAC), chronic inflammation
causes oxidative damage to DNA, leading to the p53 mutations observed in tumor
cells.(Choi, Yoon et al. 2002; Kraus and Arber 2009). ROS can also directly oxidize
and inactivate mismatch repair enzymes at protein level. (Choi, Yoon et al. 2002;
Hussain, Hofseth et al. 2003; Kraus and Arber 2009). Nitrogen oxide (NO) is a
reactive free radical produced in large amounts by the inducible nitric oxide synthase
2 (NOS2) under conditions of chronic inflammation. In its pro-tumorigenic role, NO
induces DNA strand breaks, promotes angiogenesis by induction of VEGF and
increases cell proliferation and invasion. (Hussain, Trivers et al. 2004). In its antitumorigenic role, NO can cause cytotoxic cell death of malignant cells and modulate
the immune system to eradicate the cancerous cells. There is a negative loop between
NO and tumor suppressor protein 53 (TP53), where NO causes the stabilization and
accumulation of TP53 which induces apoptosis, cell cycle arrest in the malignant
cells and represses levels of NO. (Forrester, Ambs et al. 1996; Ambs, Ogunfusika et
al. 1998).

Cytokines and chemokines

Cytokines are signaling molecules that are key mediators of inflammation or an
immune response. Upon binding to their receptor, they trigger a signaling pathway
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that leads to cell proliferation, apoptosis, angiogenesis and cellular senescence. They
broadly fall under two categories 1.) Pro-tumorigenic and 2.) Anti-tumorigenic. The
pro-tumorigenic cytokines include IL1, IL6, IL15, IL17, IL23 and tumor necrosis
factor α (TNFα) , whereas the anti-tumorigenic cytokines include IL4, IL10, IL13,
transforming growth factor (TGFβ) and interferon (IFN α). In case of CRC and CAC,
the role of IL-6, IL-1 and TNF-α in tumorigenesis has been well studied. (Tang,
Katuri et al. 2005; Popivanova, Kitamura et al. 2008; Wang, Liu et al. 2009). IL-6 is
a potent stimulator of colon cancer cell proliferation and tumor growth. (Becker,
Fantini et al. 2005) It has been implicated in pro-tumorigenic activity for many
cancers and has been found to be required for CAC in mouse models. (Grivennikov,
Karin et al. 2009) TNFs are produced during early inflammation; they trigger
production

of

other

cytokines,

chemokines

and

endothelial

adhesion

molecules.(Balkwill 2009; Li, Vincent et al. 2009).TNF-α expression increases
during colon carcinogenesis which further confirms its role in inflammation,
angiogenesis and tumor promotion. (Popivanova, Kitamura et al. 2008). One of the
key functions of TNF-α is to activate the pro-inflammatory transcription factor
NFκB. The anti inflammatory cytokines like IL-10 and TGF-β , have a general role
in tumor suppression. IL-10 exerts its anti-tumorigenic effect by down-regulating
NFκB, which results in low levels of pro-inflammatory cytokines eg- IL-6, IL-12 and
TNF-α. (Zhang 2008 December) TGF-β is another anti-inflammatory cytokine that
suppresses tumor growth by inhibiting proliferation,

promoting apoptosis,

stimulating the release of anti-inflammatory cytokines and suppressing the
expression of pro-tumorigenic cytokines.(Yang and Moses 2008) Mutation in TGF-β
pathway within epithelial cells predisposes to or facilitates colonic tumor
development and growth.
Chemokines are a class of cytokines that recruit leukocytes at the site of
inflammation. They are released by the inflammatory cells after the initial
stimulation by the cytokines. Tumors generally show high levels of chemokines that
recruit leukocytes to the site of tumor, creating a pro-inflammatory and protumorigenic environment.
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Chemokines and adhesion molecules
Early feature of inflammation is the release of chemokines like Monocyte
chemoattractant protein (MCP). These factors increase the expression of interstitial
and vascular cellular adhesion molecules like Interstitial Cellular Adhesion
Molecules (ICAM) and E-selectin that attract monocytes and immune cells.
Chemokines like MCP also induce the proliferation and pro-inflammatory gene
activation producing cytokines like IL-1α, IL-6, IL-18 etc. Other factors that
stimulate gene expression of pro-inflammatory cytokines in obese state are RONS,
oxidized lipids, free fatty acids.

Figure 1.5 Schematic diagram showing pathways linking obesity to cancer.
Insulin resistance and insulin like growth factor (IGF) are one of the several links
between obesity and cancer. High levels of circulating insulin up-regulates growth
hormone (GH) that induces hepatic production of IGF-1. IGF-1can inhibit apoptosis
and stimulate cell proliferation through several downstream signaling networks ,
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including

the

phosphatidylinsitol3-kinase

(PI3-K)-AKT

system

and

the

Ras/Raf/mitogen activated protein kinase (MAPK) systems, respectively. Leptin,
also secreted by adipocytes has mitogenic effects and anti apoptotic effects through
MAPK and PI-3-Kinase pathways. Adiponectin exerts anti-carcinogenic effect
through AMP activated protein kinase (AMPK) through receptors AdipoR1 and
AdipoR2. Adipopectin regulates growth arrest and apoptosis through p53 and p21.
IL-6 and TNF-α are the two major inflammatory cytokines that are elevated in
obesity. They exert pro-tumorigenic effect by increasing cell survival and cell
proliferation through activation of NF-κB
Animal Model
Preclinical or animal models provide a system to study the biological process of a
disease in a physiological state relevant to human beings. They provide valuable
preliminary data upon which human clinical trials can be based. However, they
should always be evaluated with regards to how relevant they are to human
conditions, and how predictive they can be for the disease process. (Green and
Hudson 2005)
With regards to colon carcinogenesis, molecular and pathological similarities to the
human condition should be observed in order to have an effective model.(Reddy
2004) Currently the APC

min+/-

mouse and azoxymethane rat model are the two main

animal models used to study the effect of dietary supplements on colon cancer.
Zucker obese rats, traditionally used to study obesity and related metabolic disorders,
offer a novel way of studying the progression of colon cancer in an altered
physiological state.

Zucker-Obese Animal Model

Zucker obese (Zk-Ob) rats are an excellent model of human obesity, and provide an
ideal opportunity to study colon carcinogenesis in an altered physiological state. The
Zucker or ‘fatty’ rat was developed in the laboratory of Zucker and Zucker in 1961,
by spontaneous mutation in a single recessive gene (Fa
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allele is designated as

normal, while fa is the fatty mutation). Zk-Ob rats inherit obesity as an autosomal
Mendelian recessive trait, fa/fa homozygous for nonfunctional leptin receptors, in
comparison to their lean (Fa/fa or Fa/Fa) counterparts.(A. 1977.) Leptin is a peptide
hormone produced by adipocytes that regulates body weight and fat metabolism by
sending signals to the hypothalamus to suppress apetite.(Arthur F. Dalley 1999) In
Zk-Ob rats, obesity is associated with metabolic dysfunction of fat metabolism
characterized by latescence and increased adipose tissue formation. (Zucker T.F.
1962. ) Genetic association of Fa gene to obesity is confirmed as Zk-Ob rats on low
fat or energy restricted diet also exhibit these symptoms. Interestingly, female
Zucker rats are sterile, which has implications for breeding programs.

Average weights of these animals at 40 weeks is 800g and 625g for Zk-Ob, and
480g and 295g for Zucker lean (Zk-Ln), males and females respectively.(Zucker T.F.
1962. ) Zk-Ob rats exhibit hyperphagia, hypertriglyceridemia, hypercholesterolemia,
hyperinsulinaemia and mild hyperglycemia at about six weeks of age. Pathological
findings at death often include hydronephrosis and polycystic kidneys, as well as
fatty livers.(Zucker T.F. 1962. ) It has been shown that Zk-Ob rats are more sensitive
to chemically induced colon carcinogenesis in comparison to their lean
counterparts.(Raju and Bird 2003) Since there is little difference in ACF number
between Fa/fa and Fa/Fa animals, the recessive gene linked to leptin receptor
deficiency is not solely responsible to higher susceptibility of colon cancer.(Weber,
Stein et al. 2000) Use of this animal model helps understanding carcinogenesis in
relation to obesity and associated metabolic disorders, providing valuable
information for treatment and prevention strategies.

Micro-RNA

Brief introduction
Micro RNAs (mi RNAs) are 19-22 nucleotide long single stranded non protein
coding RNAs that act as guide molecules in post transcriptional gene silencing by
base pairing with target mRNA leading to its cleavage or translational
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repression.(CULLEN 2003; Bartel 2004; VICTOR AMBROS 2008). With >200
members per species in higher eukaryotes, miRNAs form one of the largest gene
families accounting for approx 3% of the genome and targeting 30% of coding
regions of the genome (Lewis, Shih et al. 2003; Bartel 2004). Since their discovery
back in 1993 by Victor Ambros and colleagues, who identified the first miRNA
targeting lin-4 gene in C.elegans, miRNAs have come a long way in being
recognized as a major player in post transcriptional gene regulation. Even though we
are far from unraveling the complex role of miRNAs in gene regulation, it is evident
that they have important role in almost all biological process known, including
developmental timing, growth control, differentiation and apoptosis. Accordingly,
altered miRNA expression can have serious implication on the regular metabolism of
the cell and be a potential cause for diseases like cancer.

Gene Structure and miRNA gene transcription
Location in the genome
Early annotation to find out the genomic position of miRNAs indicated that most
them are located in the intergenic regions , although a sizeable minority are found in
the intronic region of known genes in sense or anti sense orientation.(Lau, Lim et al.
2001; Kim 2005) This implied that most of the miRNAs are transcribed as
autonomous replication unit with their own promoter. Approximately 50% of the
miRNAs are found in close proximity to known genes, (Lagos-Quintana, Rauhut et
al. 2001; Lim, Lau et al. 2005) which allows one to speculate that they are
transcribed from single polycistronic transcription unit. So the conclusion drawn was
that they can be transcribed as discrete as independent transcription unit or in a
cluster by polycistronic transcription unit.
MiRNA biogenesis
miRNAs are transcribed as long primary transcripts by RNA polymerase II;
subsequently trimmed into short hairpin intermediates called primary miRNAs and
finally processed into mature miRNAs.(Lee, Kim et al. 2004). The catalytic activity
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of the enzymes responsible for first and second miRNA processing is
compartmentalized into the nucleus and cytoplasm and is tightly regulated. (Figure
1.6)
Nuclear processing by Drosha
RNase III endonuclease Drosha is a 160 kDa protein that is highly conserved in
higher eukaryotes. (Filippov, Solovyev et al. 2000; Wu, Xu et al. 2000; Kristine R
Fortin 2002) It contains two random RNAIII domains (RIIID) and a double stranded
RNA binding domain (dsRBD) that are critical for its catalytic activity. Transcription
of miRNA genes by RNA pol II yields primary transcripts (pri-miRNA) that are
usually several kilobases long and contain a local hairpin structure. The pri-miRNA
is first cleaved by RNase III endonuclease Drosha at sites near the base of stem loop,
that releases ~60-70 nucleotide precursor miRNA. (Lee, Ahn et al. 2003) Drosha
cleaves the pri-miRNA duplex with a staggered cut typical of RNase III
endonucleases, leaving 2 nucleotide overhang at the 3’ end.(Lee, Ahn et al. 2003)
The specificity with which Drosha recognizes and cleaves pri-miRNA has been
under investigation. It was proposed on the basis of evidences from mutational
studies that the tertiary structure of the pri miRNA is the factor that decides the
specificity of Drosha. (CULLEN 2003; Lee, Ahn et al. 2003; Zeng, Yi et al. 2005)
Nuclear export by exportin-5
Following nuclear processing by Drosha, pre-miRNA is translocated to the
cytoplasm

through

the

nuclear

pore

complex

embedded

in

the

nuclear

membrane.(Nakielny and Dreyfuss 1999) Export of the pre-miRNA is mediated by
one of the nuclear transport receptors, exportin-5. (Rui Yi 2003; Lund, Güttinger et
al. 2004) . Owing to the compartmentalization of the two processing events, the
nuclear transport of pre-miRNA is a crucial step in miRNA biogenesis. (Kim 2004;
Murchison and Hannon 2004)

Cytoplasmic processing by Dicer
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On reaching the cytoplasm, pre-miRNA is cleaved by cytoplasmic RNase III
endonuclease Dicer, into ~ 22 nucleotide miRNA duplex. (Bernstein, Caudy et al.
2001; Grishok, Pasquinelli et al. 2001; Hutvágner, McLachlan et al. 2001; Ketting
2001; Knight and Bass 2001). Dicer is a highly conserved protein, found in all
eukaryotes including Saccharomyces pombe, plants and animals. Apart from the two
RIIID domains and dsRBD domain, Dicer contains long N terminal segment
containing ‘dead box RNA helicase’ domain and PAZ domain.(Zhang, Kolb et al.
2004) PAZ domain belongs to a group of highly conserved proteins called Argonaute
preteins. Structural and biochemical studies of AGOI and AGOII in D.melanogaster
revealed that PAZ domain binds to the 3’ protruding end of the small RNAs.(Song,
Liu et al. 2003; Yan, Yan et al. 2003; Lingel, Simon et al. 2004) . Usually one strand
of this short lived duplex disappears, whereas the other strand remains as mature
miRNA. Mature miRNAs are incorporated into effector complexes that are known as
microRNP (miRNA containing ribonucleoprotein

complex), migronaute’ or

microRISC (miRNA containing RNA inducing silencing complex). The strand that
gets loaded in the microRISC complex is thought to be the one that has unstable base
pairing at the 5’ end. (Khvorova, Reynolds et al. 2003; Schwarz, Hutvágner et al.
2003).
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Figure 1.6 Biogenesis of miRNA. Intergenic miRNAss are transcribed from
independent promoters as monocistronic whereas most of the miRNAs
miRNA are intragenic
and found in clusters with other genes. They are transcribed as polycistronic units.
miRNAs are transcribed by RNA polymeraseII as several kilobases long pri-miRNA.
pri
Pri- miRNA is processed in the nucleus by RNAIII endonuclease (Drosha) which
cleaves it into 60-70nt long pre-miRNA with a 2 nucleotide long overhang at the
3’end. This pre-miRNA
miRNA is transported to the cytoplasm by nuclear transporter
exportin-5.
5. In the cytoplasm, pre
pre-miRNA is cleaved by another RNAIII
endonuclease (Dicer), which generates the mature miRNA.. One of the strands of the
resulting duplex is loaded onto miRNA inducing silencing complex called miRISC.
Mature ss miRNA guides RISC to the target mRNA. After that there are several
mechanisms to downregulate mRNA/protein expression depending on the degree
de
of
sequence complimentarity. (adapted and modified from Christian Marin‐Muller
Marin
Oct
2010)
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Mechanism of miRNA mediated gene regulation
miRNA can direct RISC to downregulate gene expression by either of the two posttranscriptional mechanisms:
1.) Translational repression
2.) mRNA degradation/sequestration
Mechanism of translational repression
Once incorporated in the RISC complex, miRNA directs translational repression or
target cleavage depending on degree of sequence

complimentarity with the

target.(Hutvágner, McLachlan et al. 2001). In animals, there are several evidences
suggesting that miRNAs recognize their target mRNA by limited base pairing
between the 2-8 nucleotide seed region at the 5’end of the miRNA and the 3’ UTR of
target mRNA.(Lewis, Shih et al. 2003; Farh, Grimson et al. 2005; Stark, Brennecke
et al. 2005) The interaction between microRNPs and mRNA can have several
consequences which can be direct or indirect. Direct effects include inhibition of
translational initiation by preventing ribosome association with the internal ribosome
entry site (IRES) on the target mRNA or inhibition post translation. Post
translational repression includes premature ribosome drop off, stalled or slowed
down elongation, and/or co-translational protein degradation; the repressed mRNA
seems to be present in polyribosomes.(Nilsen 2007) (Figure 1.7)
Mechanism of mRNA degradation/sequestration
Perfect sequence complimentarity between the seed region of miRNA and the 3’UTR
of target sequence leads to the destabilization and subsequent degradation of the
transcript. miRNAs achieve this by deadenylation and decapping of the target
sequence, which results in degradation and increased turnover of the transcript. The
site of miRNA directed target sequestration are thought to be the processing bodies
(P bodies) also known as the GW bodies. The P bodies, which were originally
described in budding yeasts, are known as the cytoplasmic foci rich in decapping ,
deadenylation enzymes and exonucleases required for mRNA degradation.
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(THEOPHANY EYSTATHIOY 2003 October; Liu, Rivas et al. 2005; Eulalio,
Behm-Ansmant et al. 2007) miRNA bound to the Argonaute protein in the RISC
complex recognizes its target by complimentarity base pairing. The Argonaute
protein interacts with the GW182 protein; miRNA-mRNA and argonaute protein
complex is delivered to P bodies. In the P bodies, the mRNA is decapped and
deadenylated, subsequently degraded or held in stasis i.e spatially isolated from the
translational machinery since P bodies do not have ribosomes. (THEOPHANY
EYSTATHIOY 2003 October; Liu, Valencia-Sanchez et al. 2005) In stasis, the P
bodies are thought to act as repository for untranslated mRNAs and this has been
experimentally proved in budding yeast as well as mammalian cells.(Brengues,
Teixeira et al. 2005; Bhattacharyya, Habermacher et al. 2006)

Figure 1.7 Mechanisms of miRNA mediated repression of gene expression.
Mature single stranded miRNA loaded in a RISC complex targets and represses the
translation of mRNA in more than one way, either directly or indirectly. In direct
interaction, miRNA inhibits the initiation of translation by blocking the entry of
ribosomes into the internal ribosomal entry site(IRES). Post translational initiation,
miRNA can cause premature ribosome drop off , slowed or stalled elongation or cotranslational protein degradation. In indirect effects, miRNA targets the mRNA to P-

24

bodies where they might undergo deadenylation and decapping by the enzymes
present in the P-bodies and hence degraded or they might simply be sequestered from
the translational machinery of the cell. In the later case, which is also called ‘stasis’
the P-bodies act as repository for all those mRNA that indirectly targeted by miRNA.
(adapted and modified from Timothy Nilsen, 2007)
MiRNA signatures in cancer
Cancer is a complex genetic disease that involves aberrant expression pattern of
coding as well as non-coding genes. Earlier it was thought that only the protein
coding genes and their altered expression are involved in the pathogenesis of cancer
but with the discovery of miRNAs, the understanding of cancer mechanisms and
genomic complexity of cancer cell has completely changed. miRNAs have been
proposed to contribute to oncogenesis either as tumor suppressors (eg- miR-15a and
miR-16-1) or oncogenes ( eg- miR-155 or members og the miR-17-92 cluster). The
genomic abnormalties influencing miRNA expression in cancer are the same as for
the protein coding genes eg- chromosomal rearrangement, genomic amplification,
deletion and polymorphisms in the target site of the mRNA.(Abelson, Kwan et al.
2005; He, Jazdzewski et al. 2005)
Oncogenesis and tumor suppression - dual role of miRNAs
Majority of the miRNAs are located in regions of genomic instability that undergo
amplification or deletion which is why they have a huge role to play in the regulation
of all major cancer pathways. miRNAs lying in regions that undergo genomic
amplification act as oncogenes eg-miRNA 17-92 cluster; whereas the chromosomal
regions that undergo deletion in cancer, act as tumor suppressors eg- miRNAs 15smiR-16-1 cluster. O’Donnels in his work on cell model system showed that, human
B-cell line P493-6, which overexpresses c-MYC, shows tumor suppressor activity
through miRNA 17-92 cluster, which targets E2F1 and hence inhibits c-MYC
regulated cell proliferation.(O'Donnell, Wentzel et al. 2005) The same cluster of
miRNA when undergo amplification in the genome, act as oncogene by cooperating
with c-MYC and promoting cell proliferation and blocking apoptosis. Hence it can
25

by concluded that miRNAs can participate in distinct cancer pathways with either the
role of oncogene or tumor suppressor depending on the cell type and expression
pattern. Apart from their dual role, miRNAs can also act by targeting more than one
mRNAs at the same time and have varied response .For eg-miRNA 15a and miRNA16-1 target the anti-apoptotic Bcl-2 in leukemia cells , however in 293 fetal kidney
cells, where they are expressed, they don’t show any such response.(Calin, Liu et al.
2004). The loss of miRNA 15a and miRNA 16-1, leads to the over-expression of
Bcl-2 and consequently B-cell malignancies. In a different tissue, the overexpression of miRNA 15a and miRNA 16-1 causes the loss of activity of a tumor
suppressor that is critical to check cell proliferation and promote apoptosis in
malignant cells. There are different mechanisms that can lead to aberrant miRNA
expression in a cancerous cell-

1.) Location of miRNA in cancer associated genomic regions
More than 50% of known miRNAs are found in genomic regions that are prone to
alteration in cancer cells.(Calin, Sevignani et al. 2004). Such regions include
minimal regions of LOH (loss of heterozygosity), which are thought to harbor tumor
suppressors genes, minimal regions of amplification, which mostly harbor
oncogenes, common breakpoint region in or near possible oncogenes or tumor
suppressor genes and fragile sites.

2.) Epigenetic regulation of miRNA expression
DNA hypomethylation, CpG island hypermethylation and histone modification
losses represent epigenetic markers of malignant transformation and have been
known to be one of the mechanisms involved in miRNA abnormal expression in
cancer.((Fraga and Esteller 2005)

3.) Abnormalities in miRNA processing genes and proteins
Alterations in the proteins machinery that is involved in miRNA biogenesis, has
dramatic effects on the miRNA expression. Failure of Drosha processing step or
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Dicer mutation, could explain the downregulation of miRNA observed in primary
tumors.(J. Michael Thomson1 2006)

MiRNAs in colorectal cancer
Dysregulation of miRNA targeting tumor suppressors and oncogenes, have been
reported in carcinogenesis of colorectal cancer. Two approaches are applied today to
investigate the connection between miRNAs and CRC: functional and profiling
studies. Many proteins involved in key signaling pathways of CRC, such as members
of the Wnt/β-catenin and phosphatidylinositol-3-kinase (PI-3-K) pathways, KRAS,
p53, extracellular matrix regulators as well as epithelial-mesenchymal transition
(EMT) transcription factors (Fearon and Vogelstein 1990) are altered by miRNA in
CRC (Figure 1.8). Study of these miRNAs crucial for better understanding CRC
pathogenesis with an aim to eventually identify novel therapeutic targets. Expression
profiling of miRNAs have shown to have same potential for identification of
biomarkers as profiling of their mRNA or protein counterparts. Together these
studies help to determine the clinical prognosis of the disease along with
identification of therapeutic targets.
Few pathways that are prominent in CRC and provide evidence of involvement of
miRNAs, are detailed belowMiRNA altering regulation of Wnt/β-catenin pathway in CRC
The Wnt/β-catenin pathway plays a central role in an early colorectal tumor
development. Inactivation of the adenomatous polyposis coli (APC) gene is a major
initiating event in colorectal carcinogenesis occurring in more than 60% of colorectal
adenomas and carcinoma. (Fearon and Vogelstein 1990). According to a recent study
by Nagel et al.(Nagel, le Sage et al. 2008), miRNAs represent a novel mechanism for
APC regulation in CRC. miR-135a and miR-135b decrease translation of the APC
transcript in vitro. miR-135a and miR-135b were also found to be up-regulated in
vivo in colorectal adenomas and carcinomas and correlated with low APC levels.
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(Nagel, le Sage et al. 2008). These observations suggest that alteration in the miR135 family can be one of the early events in CRC's molecular pathogenesis.
MiRNA regulating EGFR signaling (KRAS and phosphatidylinositol-3-kinase
pathways)
The epidermal growth factor receptor (EGFR) pathway contribute to promotion and
progression of several solid tumors including colonic tumor. Stimulation of the
EGFR and KRAS signaling lead to the activation of numerous signal transduction
molecules initiating a cascade of downstream effectors that mediate tumor growth,
survival, angiogenesis and metastasis. (Ciardiello and Tortora 2008)
oncogene has been reported to be a direct target of

KRAS

the let-7 miRNA

family.(Johnson, Grosshans et al. 2005). Another miRNA associated with KRAS
regulation in CRC is miR-143.(Chen, Guo et al. 2009). Inhibition of KRAS
expression by miR-143 blocked constitutive phosphorylation of MAPK.(Chen, Guo
et al. 2009). Another central signaling pathway downstream from EGFR and
important in CRC development is the phosphatidylinositol-3-kinase (PI-3K)
pathway. The p85β regulatory subunit involved in stabilizing and propagating the PI3K signal was mechanistically proven to be a direct target of miR-126. Furthermore,
this p85β reduction mediated by miR-126 was accompanied by a substantial
reduction in phosphorylated

AKT levels in the cancer cells, suggesting an

impairment in PI-3K signaling. Another important regulatory component of the PI3K pathway, the tumor suppressor gene PTEN, is strongly repressed by miR21.(Meng F 2007 Aug) miR-21 is the miRNA most frequently up-regulated in
CRC.(Slaby O 2007; Schetter, Leung et al. 2008; Krichevsky and Gabriely 2009) It
appears that suppression of PTEN controlled by miR-21 is associated with
augmentation of PI-3K signaling and progression of CRC.
MiRNAs regulating p53 pathway
Tumor suppressor gene p53 is mutated in about 50-75% of all CRCs and many other
human tumors. (Hussain, Amstad et al. 2000) It has been speculated that p53mediated control of miRNA expression could allow it to indirectly repress target
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gene expression at the post-transcriptional level. Recently, several groups have
unraveled important aspects of connection between p53 and the miRNA
network.(Hermeking 2007). The miRNA 34a-c family was found to be direct
transcriptional targets of p53 and their targets regulate cell-cycle progression ,
cellular proliferation, apoptosis, DNA repair and angiogenesis. (Chang, Wentzel et
al. 2007). Among the downregulated targets of the miR-34 family were wellcharacterized p53 targets like CDK4/6, cyclin E2, E2F5, BIRC3 and Bcl2.Epigenetic silencing was found to be the mechanism of downregulation of miRNA
34a-c in several CRC tumors. (Lodygin, Tarasov et al. 2008) Hence, miRNA 34 a-c
was identified as a tumor suppressor that is downregulated by epigenetic silencing in
CRC, whereas in a normal cell it is associated with the p53 network.
MiRNAs in extracellular matrix breakdown and epithelial-mesenchymal transition
Epithelial mesenchymal transition (EMT) is the conversion of an epithelial cell into a
mesenchymal cell. ECM remodeling is one of the processes in tumor growth,
survival, invasiveness, and metastasizing. The key enzymes involved in ECM
breakdown are the urokinase plasminogen activator (uPA) cascade and the matrix
metalloproteinases (MMPs). (Takayama, Miyanishi et al. 2006) Morphologically,
EMT is characterized by a decrease of E-cadherin, loss of cell adhesion, and
increased cell motility leading to promotion of metastatic behavior of cancer cells
(including CRC ). (Asangani, Rasheed et al. 2007). The functional links to EMT
comes from members of the miR-200 family (miR-200a, miR-200b, miR-200c, miR141 and miR-429).
MiRNAs regulating other signaling pathways in CRC
miR-145 has been proposed as a tumor suppressor and is known to target the 3' UTR
of insulin receptor substrate-1 (IRS-1) which dramatically inhibits the growth of
colon cancer cells. (La Rocca, Badin et al. 2009) More recently, IGF-IR was proven
to be another direct target of miR-145. (Gregersen, Jacobsen et al. 2010)
Cyclooxyygenase-2 (COX-2) strongly contributes to the growth and invasiveness in
CRC. miRNA 101 was found target COX-2 directly and cause translational
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repression, hence playing the role of a tumor suppressor miRNA. (Strillacci, Griffoni
et al. 2009)

Figure 1.8 Aberrant miRNA expression affecting key pathways in colon
carcinogenesis. Several miRNAs are involved in various stages of colon
carcinogenesis. Inactivation of the APC gene of the Wnt/β catenin signaling pathway
by miRNA 135 which is up-regulated in most CRC cases, leads to the stabilization
and constitutive activation of β-catenin. This leads to transcription of genes
promoting cell proliferation. Similarly, down-regulation of miRNA 145, which
directly targets c-MYC increases cell proliferation. miRNA 143 and miRNA 126,
which are down-regulated in CRC target KRAS and p85β subunit of P-I-3 kinase
AKT pathway which leads to increased cell proliferation and survival. miRNA
21,up-regulated in majority of CRC cases directly targets tumor suppressor PTEN.
miRNA 34 a-c are p53 regulated miRNAs that target several of downstream p53
targets eg- CDK4/6, cyclin E2, E2F5, BIRC3 and Bcl-2. miRNA21 also targets
RECK amd TIMP3 which are inhibitors of invasion and malignancy . Members of
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miRNA 200 are negatively regulated by transcriptional activator ZEB3 which
induces metastasis in CRC cells.
MiRNAs as mediators of inflammation in colon cancer
Specific miRNAs can be regulated by inflammatory stimuli and alternately certain
miRNAs can act as mediators of inflammatory stimuli. Expression profiling reveal
that lipopolysaccharide (LPS) induced inflammation causes altered expression of
several miRNAs.(Taganov, Boldin et al. 2006; Sterghios A Moschos 2007). Studies
showed that treatment with either of the pro-inflammatory cytokines, IL1b or TNFα
stimulated the expression of miR-146a. (Schetter, Heegaard et al. 2010)The promoter
region for miR-146a was found to contain NFκB binding sites, indicating that NFκB
was probably responsible for driving the expression of miR-146a. (Taganov, Boldin
et al. 2006). Lung inflammation due to allergic reactions showed increased miR-21
expression.(Lu, Munitz et al. 2009). Rheumatoid arthritis which is a chronic
inflammatory autoimmune condition affecting joints and tissues showed elevated
levels of miR-146a.(Nakasa, Miyaki et al. 2008) Similarly, active inflammation in
ulcerative colitis leads to increased expression of several miRNAs, including miR21.(Wu, Zikusoka et al. 2008). It is now thought that miRNA act as mediators in
inflammation associated carcinogenesis such as colon cancer. It was seen that IL6, a
pro-inflammatory cytokine, can induce the expression of miRNA-21 in a STAT3
dependent

manner.

(Lu,

Munitz

et

al.

2009)

miRNA-155

stimulated

in

proinflammatory conditions, can target suppressor of cytokines 1 leading to the
induction of NOS2.(Wang, Zhao et al. 2009).
Distal and proximal colon gives rise to different colonic tumors
In the last two decades, histological assessment of tumors, molecular evidences from
population based and clinical studies in addition to tumor behavior studies in
preclinical models have presented a case supporting the idea of existence of distal
and proximal colonic tumor as separate diseases. (Iacopetta 2002; Li and Lai 2009).
Differences in physiology, embryology, molecular features like gene expression
pattern etc exist between the normal right and left colon that are responsible for the
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differences seen in the tumors appearing along the length of the colon. For example,
the proximal colon originates from the embryonic midgut and is perfused by the
superior mesenteric artery, whereas the distal colon derives from the hindgut and is
served by the inferior mesenteric artery. The capillary network surrounding the
proximal colon is multilayered, whereas that of the distal colon is single layered,
possibly relating to the greater water absorption and electrolyte transport capacity of
the former. (Araki, Furuya et al. 1996; Skinner and O'Brien 1996). The different
absorptive nature of right and left colon might be duw to the differences in the
average crypt length which is greater in case of distal than proximal.(Arai T 1989)
(Table 1.1)
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Table 1.1- Differences in right sided (proximal) and left sided (distal) colon.

Features

Proximal/ right sided colon

Distal/left sided colon

Anatomical
location

Right of splenic flexure Left
of splenic flexure
consisting of caecum, ascending consisting of descending colon
colon and transverse colon
and sigmoid colon

Embryologica
l origin

Midgut

Blood supply

Branches
from
mesenteric artery
Capillary network
layered

Function

Short chain fatty acid and Protein fermentation, neutral
ethanol fermentation
muco-polysaccharide
breakdown

Hindgut

superior Branches
from
inferior
mesenteric artery
is multi- Capillary network is single
layered

Average crypt Lesser compared to distal colon
length

Greater compared to proximal
colon

Stem cells are located in mid
crypt, colonocyte migration is
bidirectional i.e, up towards the
luminal surface and down
towards the crypt base

Stem cells are located at crypt
base and colonocyte migration
is upwards towards luminal
surface.

Location
of
stem cells and
Direction of
migration of
colonocyte

one
third
has Small number of mucous cells
Type of cells Lower
predominantly mucous cells and at the base, highest proportion
in the crypt
upper one third has columnar of goblet cells.
cells.
Morphology
of tumors

Sessile serrated adenomas, Traditional serrated adenomas,
hyperplastic polyps with low mostly
pedunculated
or
grade dysplasia
villiform in appearance with
high grade dysplasia

Molecular

Microsatellite

instability Chromosomal
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instability

pathway, in which the DNA
pathway for
carcinogenesis repair enzymes are silenced by
promoter methylation, causing
mutations
in
microsatellite
regions of genes involved in cell
proliferation,
apoptosis.etc.
BRAF mutation and high level
of CpG island methylation
leading to inactivation of MLH1
and MGMT, result in high and
low level MSI respectively
Gene
Genes overexpressed includeexpression
phosphosulfotransferases,
pattern
genes associated with ions,
electrolyte,
heterocyclic
compounds,
polycyclic
hydrocarbons
and
steroids
absorption e.g-cytochrome P450
family genes, glutathione Stransferase
Z1,
3-βhydroxysteroid dehydrogenase1
,
hydroxysteroid(17β)
dehydrogenase.
Tumor
behavior
in
response
to
to exogenous
agents

pathway ,in which there is
allelic loss of chromosomes
harbouring the APC, P53, KRas genes. CpG island
methylation in KRAS, leading
to microsatellite stable (MSS)
or low grade microsatellite
instable
(MSI-L)
carcinogenesis.

Genes overexpressed includephospholipase
A2,
genes
associated with cell cycle
control (cyclin D1,D2,G1,
cyclin dependent kinase 2,
PCNA), DNA replication,
DNA damage repair, DNA
adduct metabolism, TNFR2,
NF-κB, IGR-IRα, IRα, and IRβ

Azoxymethane –less tumor
Azoxymethane – more tumor
High fat diet – no significant High fat diet – promotes
effect
growth of tumor
Fish oil diet- no significant Fish oil diet- retards growth of
effect
tumor
High calcium diet- promotes
growth of ACF/tumor
Sulindac-induces
new
inflammatory
lesions
with
malignant potential

High calcium diet-reduces
growth of ACF
Sulindac-regresses
tumor
growth

Approximately 60% of CRC in high-incidence populations arise in the left colon
(distal), whereas in low-incidence regions there is a predominance of right-sided
(proximal) cases. (Haenszel W 1973). The incidence of proximal tumors in Western
countries has steadily increased in the past decade while that of distal tumors has
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shown a corresponding decrease.(Rhodes, Holmes et al. 1977).(Gervaz, Bucher et al.
2004; Fenoglio, Castagna et al. 2010). The cases have been more common at an
advanced age and in female gender of the population. (Okamoto, Stiratori et al.
2002). Taken together, the geographic location, age and gender influences on CRC
subsite distribution, in concert with the observations on proximal shift and migrant
studies, suggests the existence of two broadly different mechanisms of CRC.

Biological heterogeneity in colonic tumors depending on their spatial origin
Morphologically and histologically colonic tumors exhibit different features. The
adenomatous polyps differ in the degree of epithelial dyplasia, whereas hyperplastic
polyps have serrated appearance without dysplasia. The mixed polyps are the ones
that display both dysplasia as well as serrated appearance. Tumors could appear as
sessile, pedunculated, polypoid, villous as well as flat lesions. These features allude
to the possibility that the origin and biology of tumors differ. (Warnecke, Engel et al.
2009)

Serrated neoplasia’s (SNs) with the hyperplastic pattern are located

predominantly in the proximal colon and have superficial appearance, whereas SNs
with the adenomatous pattern were observed in the distal colon and have a protruding
appearance. (Noffsinger 2008). It has been noticed that the distribution of polyps
with high grade dysplasia is more predominant in the distal region than
proximal.(Goldstone, Itzkowitz et al. 2011)
Behavioral heterogeneity in colonic tumor
The concept that distal and proximal tumors could respond differently to cancer
preventive agents and growth modulators, has been explored in preclinical models.
Some of these require cancer induction by a carcinogen, whereas some models are
genetically

manipulated

to

address

the

role

of

specific

pathway

in

carcinogenesis.(Vignjevic, Fre et al. 2007; Raju 2008). It has been previously
established that pre-neoplastic lesions (ACF) appearing in response to chemical
carcinogens like AOM are different in distal colon compared to proximal.(Bird RP
1989) It has been reported that distally located ACF grow more rapidly in response
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to

multiple

injections

of

azoxymethane

compared

to

their

proximal

counterparts.(Raju and Bird 2003). The interpretation here could be that proximal
colonic regions resist growth modulating environment and respond slowly or that the
test agent may not be as readily available to proximal colonic tissue. For e.g; high fat
tumor promoting diet promotes the growth of distally located tumors and it is less
effective in proximal tumors.(Kim, Chung et al. 1998; Hambly, Saunders et al.
2002). A high fish oil diet in a high risk preclinical model of colon carcinogenesis is
more effective in retarding the growth of distal developing tumors. (Hong, Chapkin
et al. 2001) Similarly a high calcium diet retards the growth of ACF in distal colon
and tumors whereas has an opposite effect on the ACF or tumors developing in the
proximal region. (Li, Kramer et al. 1998; Pierre, Taché et al. 2003) Recently, it was
observed that a non-inflammatory drug Sulindac is able to regress distal colonic
tumor in azoxymethane injected mice, whereas in the proximal region it induces new
inflammatory lesions which develop into adenocarcinomas in upto 18-25% of p53 or
mismatch repair deficient mice.(Mladenova, Daniel et al. 2011).In Zucker obese
model, distally located tumors exhibited a phenotype compatible to enhanced growth
than the proximal tumors. TNFα signaling pathway, insulin and expression of IGF
receptors were higher in the distal colonic tumors.(Jain and Bird 2010) The most
notable finding was that the ERK1 and 2 were differently expressed. Elevated
expression of TNFR2, NF-κB, IGR-IRα, IRα, and IRβ was seen in the distal tumor
mass compared to proximal tumor. Distal tumor showed high levels of NF-κB, IKKβ
and lower level of IκB-α, which suggests that the pathway leading to activation of
NFκB and subsequent survival genes is more active in distal colonic tumor compared
to proximal. The presence of elevated levels of insulin, IGF-1R and TNF-α in the
distal colon could also act synergistically to provide superior survival conditions to
developing preneoplastic lesions in distal colon compared to proximal colon. (Jain
and Bird 2010)
Molecular heterogeneity evident in profiling studies in clinical system
The distinct clinico-pathological characteristics as well as differences seen in tumor
behavior along the colonic axis, is also reflected in the pattern of gene expression.
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Some of these differences are thought to be acquired embryonic and post natal
development, whereas some are speculated to be the result of interaction with the
environmental risk factors, aging, diet etc. Microarray profiling of human colonic
tumor showed >1000 genes that were differentially expressed in distal versus
proximal tumor, seventy percent of which were highly expressed in distal colon
compared to proximal colon.(Joyce and Pintzas 2007). The genes found to be
differentially expressed in distal and proximal tumor are known to be involved in
many cellular processes which include cell cycle, proliferation, cell death, response
to external stimuli, stress response, and DNA replication and damage repair. These
are also implicated in key signaling pathways known to be involved in colon
carcinogenesis eg-EGF. The genes found to be differentially expressed in distal and
proximal tumor are known to be involved in many cellular processes which include
cell cycle, proliferation, cell death, response to external stimuli, stress response, and
DNA replication and damage repair. These are also implicated in key signaling
pathways known to be involved in colon carcinogenesis eg- EGF, TGF-β, Wnt, Ras,
insulin and integrin signaling.(Glebov, Rodriguez et al. 2003).
miRNA profiling in distal and proximal colonic tumor: evidences from clinical
studies
In recent years miRNAs have been been used as diagnostic tool to differentiate
between right (proximal) and left sided (distal) colonic tumors. A comparitive study
between normal colonic tissue and colon tumor from distal and proximal regions,
showed several unique miRNAs that were differentially expression for microsatellite
instability positive (MSI+) colon tumors found mostly in the proximal .There were
several miRNAs that were differentially expressed for KRAS2-mutated colon
tumors, and 139 miRNAs were differentially expressed for TP53-mutated colon
tumors mostly seen in the distal region of the colon. (Slattery, Wolff et al. 2011).
miRNA profiling of colon cancer samples characterized by microsatellite
stability(MSS) and samples characterized by microsatellite instability showed
differential expression of several miRNAs. miRNA 17-92 family showed
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upregulation in MSS colonic tumor which is predominantly found in distal colonic
region.
miRNA has been used as diagnostic tool and biomarker for prognosis and predicting
clinical

outcomes in colon cancer. With evidences from clinical and preclinical

models supporting the concept of proximal and distal colonic tumor as distinct
diseases, there is need to get deeper insight into the regulation of gene expression in
these two regions of the colon. miRNA have shown distinct expression pattern in
these regions further strengthening the molecular evidences in this regard. However,
they are very few evidences from animal model study that look into miRNA
expression pattern in distal and proximal colon in control or altered physiological
state.

38

CHAPTER 3
DESIGN AND METHODOLOGY

Animals
Female Zucker obese fa/fa (Zk-Ob) and lean (Zk-Ln) rats (n=10/group), weighing
approximately 300 and 80 Kg respectively ,were obtained from Charles River
Laboratories (Montreal, QB, Canada) at 12 weeks of age. They were housed in
standard plastic cages with woodchip bedding and stainless steel wire mesh lid in the
Biology Animal facility, University of Windsor, under controlled environmental
conditions (22° C temperature, 50% humidity, 12 hour light/dark photo-period).
Animal care and all investigative procedures adhered to guidelines of the Office of
Research Ethics and Animal care committee of University of Windsor (AUPP# 1019) and the Canadian Council of Animal Care. Body weights of the animals was
monitored twice a week and finally at termination.
Following one week of acclimatization, animals were terminated by CO2
asphyxiation. After recording weight of the body, liver and kidney, blood was
obtained in heparinized or EDTA vacutainer tubes (BD Vacutainer Systems, NJ from
a cardiac puncture using a multiple sample Luer adapter). Organs collected were
stored in liquid nitrogen and kept at -80°C for future studies.
Blood analysis
Blood samples were centrifuged for 10 min at 2000 rpm to separate plasma, which
was then aliquoted. Samples were either stored for further analysis at -80ºC, or sent
to Animal Health Laboratories (University of Guelph, Guelph, ON) for biochemical
analysis of inflammatory cytokines (Interleukins), adhesion molecules like inter
cellular adhesion molecules (ICAM), chemokines, Monocyte Chemoattractant
Protein (MCP) ( appendix A.1)
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Colon preparation
Colon from each animal was removed, flushed with cold phosphate buffer saline and
placed on a cold plate set at 4°C. A longitudinal cut was made from the rectal to the
ceacal end. Mucosa from the colon was scraped separately from distal and proximal
region of the colon and snap from in liquid nitrogen as well as RNA later (Sigma) for
biochemical and molecular analysis.
Total RNA isolation
50-100 mg of frozen tissue was used to isolate total RNA using miRNeasy Mini Kit
(Qiagen). The miRNeasy Mini Kit combines phenol /guanidine based lysis of
samples and silica-membrane based purification of total RNA. Tissue samples were
homogenized in QIAzol Lysis Reagent which is a monophasic solution of phenol and
guanidine thiocyanate similar to TRIazol, which facilitates lysis of tissues, inhibits
RNases, and removes most of the cellular DNA and proteins from the lysate by
organic extraction. After addition of chloroform, the homogenate was separated into
aqueous and organic phases by centrifugation. RNA was partitioned to the upper,
aqueous phase, while DNA was partitioned to the interphase and proteins to the
lower, organic phase or the interphase. The upper, aqueous phase was extracted, and
ethanol (50%) was added to provide appropriate binding conditions for all RNA
molecules from 18 nucleotides (nucleotide) upwards. The sample was then applied to
the RNeasy Mini spin column, where the total RNA binds to the membrane and
phenol and other contaminants were efficiently washed away. High-quality RNA was
then eluted in RNase-free water.
MiRNA isolation
The flow through from the above step (using RNeasy Mini spin column), was mixed
with 0.65 volumes (450µ l) of 100% ethanol and vortexed. This sample was loaded
into RNeasy MinElute spin column which was placed in 2ml collection tube. The
samples were centrifuged for 1 minute at approximately 8000 x g (10,000 rpm) at
room temperature (15-25°C). Flow through was discarded. Column was washed
twice with 700µl of RWT buffer (wash buffer containing guanidine thiocyanate).
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Column was finally washed with 80% ethanol. miRNA was eluted in 30µ l of RNase
free water.
Spectrophotometric quantification of miRNA-enriched fractions
MiRNA enriched fractions prepared is assumed to contain many types of small RNA,
including miRNA, snoRNA, and piRNA, as well as tRNA and a significant
proportion of the 5S and 5.8S rRNA. Larger species, including tRNA, dominate the
OD measurement of these fractions and also gel staining or assays which use RNAbinding dyes. For this reason, it is not possible to quantify miRNA using OD
measurements. Hence to quantify miRNA, qRT PCR was performed using miScript
System (Qiagen).
MiRNA to cDNA (Reverse-transcription step)
10-20 ng of miRNA enriched fraction of total RNA was converted to cDNA using
RT2 mi RNA first strand kit (Qiagen) and primer specific probes. miScript Reverse
Transcriptase Mix is an optimized blend of enzymes comprising of a poly (A)
polymerase and Reverse Transcriptase. The buffer system enables maximum activity
of both enzymes besides containing Mg2+, dNTPs ,oligo-dT primers, and random
primers. Unlike mRNAs, miRNAs are not polyadenylated in nature.During the
reverse-transcription step, miRNAs are polyadenylated by poly (A) polymerase.
Reverse transcriptase converts RNA (including precursor miRNA, mature miRNA,
other small noncoding RNA, and mRNA) to cDNA using oligo-dT and random
primers. Polyadenylation and reverse transcription are performed in parallel in the
same tube. The oligo-dT primers have a universal tag sequence on the 5' end. This
universal tag allows amplification in the real-time PCR step.
For each 10µl reaction, the components (Appendix B.1) were added to a regular pcr
tube, mixed and stored in ice. The reaction was incubated at 37°C for 60 minutes and
then for 5 minutes at 95°C to inactivate Reverse Transcriptase.
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Real Time Quantification of miRNA
MiRNA abundance was quantified using conventional two step quantitative reverse
transcriptase real time PCR (q PCR) using miScript housekeeping primer assay for
small nuclear RNA (RNU6 and 4.5s_V1). Template cDNA was characterized by qRT
PCR using RT² SYBR Green/ROX qPCR Master Mix on the 7500 FAST Real-Time
PCR System (Applied Biosystems). miRNAs were amplified using the miScript
Universal Primer (Qiagen) , which primes from the universal tag sequence, together
with the miScript Primer Assay for housekeeping small nuclear RNA.
Reaction setup for real-time PCR based quantification of miRNA (Appendix B.2)
For 20µl reaction volume, the components are added to a PCR tube, mixed
thoroughly and kept in ice.
Cycling conditions for real-time PCR for miRNA quantification – (Appendix B.3)
Manual C T threshold value was adjusted to 0.02, again as per instrument
specifications. Fold change in gene expression was calculated using the ∆∆ Ct
method and analyzed with Sequence Detection System software (SDS version 2.0.5
Applied Biosystems).
MiRNA Rat Cancer PCR Array
The differential expression of miRNA in colonic mucosa tissue was profiled using
RT2 miRNA PCR Array system (SAbioscience / Qiagen). The universal primer in
every assay of the RT2 mi RNA PCR Arrays is specific for the unique sequence
incorporated into the cDNA by the universal RT primer in the RT2 mi RNA First
Strand Kit.
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Step 1- cDNA First Strand synthesis (Appendix B.4)
The contents were mixed, followed by brief centrifugation. The samples were then
incubated at 37°C for 2 hours; and then heated at 95°C for 5 minutes to degrade the
RNA and deactivate the Reverse Transcriptase. The samples were then chilled on ice
and 90µl of RNase free water was added to each 10 µl reaction volume.
Step 2- Real Time PCR
The 96 well RT2 miRNA cancer PCR array (SAbiosciences /Qiagen) was used for
screening cancer miRNA coding genes from distal and proximal mucosa samples
obtained from Zk-Ob and Zk -Ln rats.
The components for were added to a 15 ml tube and mixed thoroughly with a pipette
as per the manufacturer’s protocol. (Appendix B.5)
25µ l of the cocktail was added to each well of the 96 well Rat Cancer RT2 miRNA
PCR Arrays (stored at -20°C). The array profiles the expression of 88 miRNA
sequences (annotated by the Sanger miRBase Release 14.) which are implicated in
cancer and related pathways directly or indirectly. Cycling conditions for real time
PCR for the array experiment (Appendix B.6).
The 10-minute step at 95°C was required to activate the HotStart DNA polymerase.
SYBR Green fluorescence was detected and recorded from each well at the annealing
step for each cycle. The threshold cycle C T was calculated using the instrument
software, i.e Sequence Detection System software (SDS ver 2.0.5) Applied
Biosytems. To define the Baseline, the Linear View of the amplification plots were
used and the instrument was set to use the readings from cycle number three (3) to
cycle number fifteen (15).Other amplification kinetics were measured on Applied
Biosystems 7500 FAST sequence detector and analysed with Sequence Detection
System software (SDS ver 2.0.5) Applied Biosytems. Data was analysed using ∆∆Ct
method.
MiRNA Sequence Specific Assays contained within each RT2 mi RNA PCR Array
include one universal primer and one gene-specific primer for each mi RNA
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sequence. Details of array layout (Appendix B.7) Controls used in the array are a
panel of housekeeping Assay consisting of small nuclear RNA housekeeping assay
panel which include Rnu6, U87, 4.5S_V1 and Y1. Duplicate Reverse Transcription
Control (RTC) in the rray tests the efficiency of first strand reaction with a primer
set miRNA called External RNA Control (ERC) detecting the cDNA template
synthesized. Positive PCR Control (PPC) tests the efficiency of the polymerase chain
reaction itself using a pre-dispensed artificial DNA sequence and the primer set that
detects it.
Statistical Analysis
DataAssist TM v3.0 Software (Applied Biosystems) was used as analysis tool for
sample comparison using relative comparative C T (∆∆Ct ) method (Livak and
Scmittgen, 2008) . It provides relative quantification analysis of gene expression
through combination of statistical analysis by performing t-test for biological group.
For graphical representation, relative quantification (RQ plot) was plotted that
displays RQ (fold change) versus target assay. The cluster analysis and heat map was
created using the DataAssistTM software v3.0 that graphically displays results of
unsupervised hierarchical clustering. Distance between samples and assays were
calculated for hierarchical clustering based on the ∆C T values using Pearson’s
Correlation application of the DataAssist software.
Target Prediction by bioinformatics analysis
Several algorithms were used to predict potential targets of miRNA, such as
miRanda (http://miRNA.sanger.ac.uk/targets/v4/), PicTar (http://pictar.bio.nyu.edu/),
and TargetScan 3.1 (http://www.targetscan.org/). Potential target sequences were
pooled for both rat and human mRNA and only those targets were considered that
were conserved between the two species. Finally, the predicted targets were aligned
against published Affymetrix gene expression profile from rat distal and proximal
colonic tissue.(Su, Bush et al. 2007).
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Chapter 4
ANALYSIS OF RESULTS

Body weight, liver weight, kidney weight
The average body weight of Zk-Ob (fa/fa) rats was 315gm. The average liver and
kidney weight was 19.286 gm and 4.536 gm respectively. The average body weight
of Zk-Ln(Fa/fa) rats was 86gm.The average liver and kidney weight was 10.77 gm
and 3.87 gm respectively.
Blood parameters
A multiplex assay using antibody bead array technology (Appendix A.1) was
used to assess the levels of specific cytokines and markers

associated with

obesity and inflammation eg- ICAM-1, E-selectin, IL-1α, IL-6 and MCP-1. The
markers that showing significantly higher levels in obese plasma compared to
lean are as follows:
ICAM - obese 11569.8 pg/mol ±1582.64 versus lean 7810.48 pg/mol ±623.67
MCP - obese 389.06 pg/mol ±161.16 versus lean 167.55 pg/mol ± 19.95
E-Selectin - obese 94405.26 pg/mol ± 8415.09 versus lean 87697.38 pg/mol ±
5588.32
IL-1α - obese 1996.3275 pg/mol ± 987.09 versus lean 1170.4025 pg/mol ± 284.98
IL-6 - obese 1875.13 pg/mol ± 887.62 versus lean 711.8825 pg/mol ± 90.37
Results indicate a significant rise in levels of inflammatory cytokines (IL-1α, IL-6),
chemokines (MCP) and cellular adhesion molecules (ICAM and E-selectin) in the
blood plasma of Zk-Ob rats compared to their lean (control) counterparts.
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Differential expression of miRNA in Zk-Ob and Zk-Ln liver
This study was carried out to meet specific aim1 i.e establishing method of isolation and
quantification of miRNA in rat tissue. Liver tissue was used to optimize the miRNA
isolation since it is a large organ that provides sufficient start material to establish a
methodology that was subsequently used to meet specific aim 2 and 3. Liver steotosis or
abnormal accumulation of fats in the hepatic cell is a common symptom seen in obesity.
It is a part of metabolic syndrome associated with obesity and is speculated to play an
important role in inflammation associated metabolic disorders. Hence, liver along with
colon can provide an insight into the role of obesity in regulation of miRNA expression.
The miRNA expression pattern of Zk-Ob and Zk-Ln liver tissue, showed that 20
miRNAs were significant up-regulated in Zk-Ob liver compared to Zk-Ln. These
include miRNA 125a-5p, miRNA 132, mi RNA 137, miRNA 146 b, miRNA 15b, mi
RNA 181a, mi RNA 181b, miRNA 183, miRNA 191, mi RNA 199a-3p, miRNA
199a-5p, miRNA 200, miRNA 21, miRNA 218, mi RNA 223, mi RNA 23a, miRNA
27a, miRNA 34a, miRNA 429 and miRNA 96. (Figure 4.1) There were few that
showed more than 2 fold up-regulation but were not found to be statistically
significant. Similarly, few miRNA were found to be almost two fold down-regulated
in Zk-Ln, though not significant. Out of the 20 miRNAs that showed significant
differential regulation in Zk-Ob liver compared to lean, 3 prominent ones, namely
miRNA 21, miRNA 199-3p and miRNA -5p were picked for independent validation
studies. In their individual validation studies, all three of them showed significant
up-regulation in Zk-Ob liver compared to Zk-Ln liver in accordance with the array
studies (Figure 4.2).
The method of miRNA isolation and quantification was successfully established
(specific aim1). Several miRNAs were found up-regulated in obese liver compared to
lean, establishing the fact that obesity influences miRNA expression irrespective of
genotype.(Table 4.1) Through validation studies, it was further confirmed that
miRNA 21, miRNA 199-3p and miRNA 5p are up-regulated under obese conditions.
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RQ Plot (Study; Lean Obese LIver, Reference; Lean, Plot Type: RQ vs Target, Graph Type: Linear
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Figure 4.1 Differential expression of miRNAs in liver tissue of Zk-Ob versus ZkLn. miRNA abundance in the samples was normalized using miRNA 4.5s_V1 as
endogenous control. The abundance of each of the candidate miRNAs is represented
as linear RQ or fold change of obese compared to lean ( reference sample ). P-values
are calculated using student t-test application of DataAssist software v3.
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Figure 4.2 Validation of selected miRNAs in independent sample set. miRNA
was isolated from idependent set of liver tissue from Zk-Ob and Zk-Ln rats (n=3).
Individual miRNA primer assays for miRNA 21, miRNA, 199-3p and miRNA 1995p were used to measure of miRNA abundance in obese versus lean liver tissue using
q RT PCR. Here the individual miRNA abundance is plotted against fold change
(RQ). Data was normalised using 4.5s_v1 as endogenous control and significance
was calculated by student t-test(**p<0.05, **p<0.01, ***p<0.001 )

Panel (a)-

miRNA 21 shows approx.1.5 fold abundance in Zk-Ob liver compared to Zk-Ln;
panel (b.) miRNA 199-3p shows 4 fold abundance in Zk-Ob liver compared to ZkLn; panel(c.) miRNA 199-5p shows 4 fold abundance in Zk-Ob liver compared to
Zk-Ln.
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Table 4.1-Significantly up-regulated miRNAs in Zk-Ob liver compared to Zk-Ln liver and their function/target

miRNA
miRNA
125a-5p

Fold
change
6.32

Direction
upregulation

Adjusted
P-value
0.02

miRNA 132

7.91

upregulation

0.003

miRNA 137

40.77

upregulation

0.015

Cellular function/target

Reference

directly
targets
oncogene
ERBB2 in gastric carcinoma
cells, negatively regulates cell
proliferation and metastasis,
EGFR
regulated
tumor
suppressor,
regulates
the
inflammatory response, lipid
uptake
in
monocytes/macrophages

(Chen, Huang et al. 2009;
Nishida, Mimori et al.
2011; Guofu Wang 2009
October)

targets tumor suppressor protein (Shaked, Meerson et al.
rein retinoblastoma (pRb) in 2009; Park, Henry et al.
panc nreatic cancer cells, thus 2011)
increasing cecell proliferation,
potentiates Cholinergic AntiInflammatory Signaling by
Targeting Acetylcholinesterase

acts as a tumor suppressor in (Liu, Lang et al. 2011;
colon and is often silenced by Zhang, Hao et al. 2011)
promoter methylation, targets
carboxyl
terminal
binding
protein1 that acts as corepressor for many tumor
suppressor genes, targets Cdc2
expression, induces G1 cell
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cycle arrest and inhibits
invasion in CRC cells.
miRNA
146b

7.82

upregulation

0.022

supresses NF-κB activity in (Bhaumik, Scott et al.
breast cancer cells,expressed in 2008; Dipa Bhaumik1
response to rising inflammatory 2009)
cytokine levels as part of
negative feed back loop that
restrains excessive senescence
associated secretory phenotype.

miRNA 15b

6.82

upregulation

0.024

E2F
(promotes
cell (Satzger, Mattern et al.
proliferation) regulated which 2010; Ofir, Hacohen et al.
in turn regulates E2F activity, 2011)
associated with increased cell
proliferation and decreased
apoptosis.

miRNA
181a

7.92

upregulation

0.037

induced by Wnt/β
signaling, including
over-expression.

miRNA
181b

3.9398

upregulation

0.013

expression promotes G1 to S (Gelsomina
transition, targets CBX7 and 2010 )
cell death associated genes egPCD4, BCl11etc

miRNA 183

12.32

upregulation

0 0.009

functions as oncogene by (Sarver, Li et al. 2010)
targeting transcription factor
EGR1,PTEN and promoting
cell migration
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catenin (Bioscience 2011)
Wnt10

Mansueto

upregulation

0.014

oncogene that promotes cell (Elyakim, Sitbon et al.
proliferation
and
inhibits 2010;
Wynendaele,
apoptosis in hepatocarcinoma, Böhnke et al. 2010)
targets MDM4
which down-regulates p53.

miRNA 199- 19.97
3P

upregulation

0.006

(Fornari, Milazzo et al.
2010; Shatseva, Lee et al.
2011)

miRNA 199- 15.77
5p

upregulation

0.008

regulates cell proliferation and
survival by targeting Caveolin2,targets mTOR and c-Met in
human hepato-carcinoma cells
targets
hypoxia
inducible
factor-α
in
hepatocellular
carcinoma, discoidin domain
receptor-1 (DDR1) tyrosine
kinase, involved in cell
invasion-related
signaling
pathway is targeted by miRNA
199-5p,targets HES which
negatively
regulates
cell
proliferation

miRNA 200c 12.74

upregulation

0.009

(Howe, Cochrane et al.
2011)

upregulation

0.036

suppresses E-Cadherin and
other genes related with EMT
transition, by targeting ZEB1
and ZEB2
acts as oncogen by targeting
tumor
suppressor
gene
tropomyosin
(TPM1),
programmed
cell
death
1(PCD4) and maspin, both
implicated in metastasis and
invasion,directly targets PTEN
tumor
suppressor,
EGFR

miRNA 191

miRNA 21

3.97

4.98
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(Livia Garzia 2009; Qingli
Shen1 2010; Wang, Song
et al. 2011)

(Zhu, Wu et al. 0000; Hurt
and Farrar 2007; Meng,
Henson et al. 2007)
9:227 (Seike, Goto et al.
2009)

regulated anti apoptotic factor

miRNA 218

8.09

upregulation

0.036

targets EGFR that regulates
NF-κB
activity
and
is
associated
with
apoptotic
response, tumor suppressor
activity in lung squamous cell
carcinoma, targets mTOR

(Davidson, Larsen et al.
2010; Gao, Zhang et al.
2010; Uesugi, Kozaki et
al. 2011)

miRNA 223

7.92

upregulation

0.03

targets starthmin1(onco-protein)
in
hepatocarcinoma
cells,
promotes
gastric
cancer
invasion and metastasis by
targeting tumor suppressor
EPB41L3, negatively correlated
with oncogene c-myc, targets
tumor suppressor FBW7, that
targets oncoproteins like cyclin
E, c-myc for degradation,
induces expression of GLUT3

(Wong, Lung et al. 2008;
Lu, Buchan et al. 2010;
Xu, Sengupta et al. 2010;
Li, Zhang et al. 2011;
Zhao WY 2011 Feb)

miRNA 23a

3.95

upregulation

0.013

acts as tumor supprerssor by
promoting and antiapoptotic (Zhu, Liu et al. 2010)
factor
in
hepatocellular
carcinoma cells, downregulates
interleukin -6 receptor

miRNA 27a

5.00

upregulation

0.035

oncogenic, targets ZBTB10 and
Myt1
which
cataylses (Sudhakar Chintharlapalli
phosphorylation of cdc2 to 2009, october 15)
inhibit progression of cells from
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G2 to M phase
miRNA 34a

3.14

upregulation

0.042

p53
dependent
tumor
suppressor,
(Munekazu Yamakuchi*†
targets CDK4/6, E2F5, BcL2, June 25, 2008)
SIRT1 (negative regulator of
apoptosis
under
stress
conditions)

miRNA 429

32.08

upregulation

0.006

modulates expression of c-myc,
playes important role in (Sun, Wang et al.)
pathogenesis
of
gastric
carcinoma

miRNA 96

24.84

upregulation

0.006

targets KRAS, acts as tumor
suppressor in pancreatic cancer (Yu, Lu et al. 2010)
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Differential expression of miRNA in distal and proximal colon of Zucker lean
rat (control)
This study was conducted to determine the miRNA expression profile in right and
left sided colon using Zk-Ln rats as control. It was found that 9 out of the 88
miRNAs on the array showed statistically significant fold increase (P< 0.05) in
proximal colonic mucosa compared to distal. There were few miRNAs that showed
down-regulation for eg- miRNA 221 and miRNA 222 showed 0.6223 and 0.2513
down-regulation respectively. However, they did not show any statistically
significance. miRNAs that showed significant up-regulation(P <0.05) in proximal
colon mucosa compared to distal include miRNA-143, miRNA-152, mi-RNA 206,
miRNA-218, miRNA- 223, miRNA 29b, miRNA-30c,miRNA-363, miRNA 335.
(Figure 4.3) There were atleast 10 more miRNAs that showed more than 2 fold upregulation but they were all found to be statistically insignificant.
Looking at the lean (control) group alone, it can be concluded that miRNA are
differentially expressed in distal and proximal regions of the colon (specific
aim2).(Table 4.2) The possibility of few or all of these miRNAs serving as
biomarkers for specific colonic regions would depend on the consistency of their
trend of expression under other physiological conditions.
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Figure 4.3 Differential expression of miRNAs in Zk-Ln proximal colonic mucosa
versus Zk-Ln distal colonic mucosa. miRNA abundance in the samples was
normalized using miRNA 4.5s_V1 as endogenous control. The abundance of each of
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ln proximal
colonic mucosa compared to Zk-Ln distal colonic mucosa (reference sample). Pvalues are calculated using student t-test application of DataAssist software v3.0.
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Table 4.2- Significantly up-regulated miRNAs in Zk-Ln proximal colon compared to Zk-Ln distal colon and their
function/targets
mi RNA

Fold
change

Direction

Adjusted
-P value

Cellular function/target

Reference

miRNA 143

25.74

upregulation

0.046

targets
KRAS
oncogene, (Ng, Tsang et al.
operational in colon cancer, targets 2009; Gao, Zhang et
DNA methyl transferases3 in colon al. 2011)
cancer

miRNA 152

8.04

upregulation

0.046

induces aberrant DNA methylation (Jinfeng Huang July
in Hepatitus B virus related 2010)
Hepatocarcinoma by targeting
DNA methyl transferaseI

mi RNA 206

32.32

upregulation

0.032

targets
notch3
,activates (Song, Zhang et al.
apoptosis,inhibits
tumor
cell 2009)
migration

miRNA 218

130.73

upregulation

0.046

targets EGFR that regulates NF-κB
activity and is associated with
apoptotic
response,
tumor
suppressor
activity
in
lung
squamous cell carcinoma, targets
mTOR

(Davidson, Larsen et
al. 2010; Gao, Zhang
et al. 2010; Uesugi,
Kozaki et al. 2011)

miRNA 223

41.17

upregulation

0.047

targets starthmin1(oncoprotein) in
hepatocarcinoma cells, promotes
gastric cancer invasion and
metastasis by targeting tumor
suppressor EPB41L3, negatively
correlated with oncogene c-myc,

(Wong, Lung et al.
2008; Xu, Sengupta
et al. 2010; Li,
Zhang et al. 2011;
Zhao WY 2011 Feb)
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targets tumor suppressor FBW7,
that targets oncoproteins like cyclin
E, c-myc for degradation, induces
GLUT4 expression
miRNA 29b

10.12

upregulation

0.047

induces
global
hypomethylation
by
targeting DNMT1

miRNA 30c

16.28

upregulation

0.032

associated with HER and RAC1 (F
Germán
signaling pathways in breast cancer Rodríguez-González
2011)

miRNA 363

16.57

upregulation

0.032

regulated by insulin growth factor (Adhip
receptor IGF-R, down-regulated in Majumdar1
colon cancer.
2010 )

miRNA 335

258.02

upregulation

0.047

miRNA-335 acts as a metastasis
suppressor in gastric cancer by
targeting Bcl-w
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DNA (Garzon, Liu et al.
directly 2009)

PN
April

(Xu, Zhao et al.
2011)

Differential expression of miRNA in distal and proximal colon of Zk-Ob rats
under conditions of chronic inflammation
The aim of this study was to identify the key miRNAs that are differentially
expressed in proximal versus distal colon under obese conditions. It was found that
15 out of the 88 miRNAs on the array, showed significant fold decrease (P<0.05) in
proximal colon compared to distal colon. (Figure 4.4) Interestingly, most of the
miRNAs were found to be down-regulated in proximal colon compared to distal.
Among the miRNAs that were found to be significantly down-regulated, are miRNA
125a-5p, miRNA 132, miRNA 133b, miRNA 181d, miRNA 183, miRNA199a-5p ,
miRNA 21, miRNA 223, miRNA301a, miRNA320, miRNA 34a, miRNA 378,
miRNA 708, miRNA 7a and miRNA 92a. miRNA 223, that was found significantly
up-regulated in lean proximal colon was found significantly down-regulated in
proximal colon under conditions of obesity. miRNA 21, which is associated with
inflammation was down-regulated in proximal colon of Zk-Ob rat as well. Most of
the other miRNAs that were down-regulated in proximal colon compared to distal
were not statistically significant.
In this study, several observations were made regarding the role of obesity in
regulation of miRNA expression. Firstly, obesity seems to have a profound on
several miRNAs in the colon which shows that inflammation is a key factor
involved. (Table 4.3) Secondly, miRNA 223 that was significantly up-regulated in
proximal colon compared to distal in the control lean group, was significantly downregulated under obese conditions. Interestingly, this miRNA is also down-regulated
in hepatocellular carcinoma, where it acts as tumor suppressor by directly targeting
Stathmin1 oncogene. (Wong, Lung et al. 2008) Similar trend was observed in case of
few others miRNAs also, however they were not significant.
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Figure 4.4 Differential expression of miRNAs in Zk-Ob proximal colonic mucosa
versus Zk-Ob distal colonic mucosa. miRNA abundance in the samples was
normalized using miRNA 4.5s_V1 as endogenous control. The abundance of each of
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ob proximal
colonic mucosa compared to Zk-Ob distal colonic mucosa (reference sample). Pvalues are calculated using student t-test application of DataAssist software v3.0
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Table 4.3- Significantly down-regulated miRNAs in Zk-Ob proximal colonic mucosa compared to Zk-Ob distal colonic
mucosa
miRNA

Fold
regul
ation

Direction

P value

Cellular function/target

Reference

(Chen, Huang et al.
2009;
Nishida,
Mimori et al. 2011;
Guofu Wang 2009
October)

0.004

downregulation

0.008

directly targets oncogene ERBB2 in gastric
carcinoma cells, negatively regulates cell
proliferation and metastasis, EGFR regulated
tumor suppressor, regulates the inflammatory
response,
lipid
uptake
in
monocytes/macrophages

miRNA 132 0.009

downregulation

0.023

targets
tumor
suppressor
protein (Shaked, Meerson et
retinoblastoma (pRb) in pancreatic cancer al. 2009; Park, Henry
cells, thus increasing cell proliferation, et al. 2011)
Potentiates Cholinergic Anti-Inflammatory
Signaling by targeting acetylcholinesterase

0.010

downregulation

0.048

targets pro survival signals MCL-1 and (Melissa
Crawford
BCL2L2 in lung cancer
August 2009

miRNA125a-5p

miRNA
133b

)
miRNA
181d

0.024
7

miRNA 183 0.032

downregulation

0.049

targets
tissue
inhibitor
of
matrix (Wang, Hsu et al.
metalloproteinase
(TIM3)
in 2010; Junfang Ji
hepatocarcinogensis, induced by β catenin 2011 January 18)
signalling

down-

0.013

Sarver, L i et al. 2010)
functions as oncogene by targeting
transcription factor EGR1 and promoting cell
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9

regulation

migration

miRNA
199a-5p

0.003
2

downregulation

0.008

targets hypoxia inducible factor-α in (Qingli Shen1 2010)
hepatocellular carcinoma, discoidin domain
receptor-1 (DDR1) tyrosine kinase, involved
in cell invasion-related signaling pathway is
targeted by miRNA 199-5p

mi RNA 21

0.012

downregulation

0.049

acts as oncogene by targeting tumor
suppressor
gene
tropomyosin(TPM1),
programmed cell death 1(PCD4) and maspin,
both
implicated
in
metastasis
and
invasion,directly
targets
PTEN
tumor
suppressor, EGFR regulated anti apoptotic
factor

(Zhu, Wu et al. 0000;
Hurt and Farrar 2007;
Meng F 2007 Aug;
Seike, Goto et al.
2009)

mi RNA
223

0.008

downregulation

0.024

targets
starthmin1(oncoprotein)
in
hepatocarcinoma cells, promotes gastric
cancer invasion and metastasis by targeting
tumor suppressor EPB41L3, negatively
correlated with oncogene c-myc, targets tumor
suppressor FBW7, that targets oncoproteins
like cyclin E, c-myc for degradation, induces
GLUT4 expression

(Wong, Lung et al.
2008; Xu, Sengupta
et al. 2010; Li, Zhang
et al. 2011; Zhao WY
2011 Feb)

miRNA 301 0.005

downregulation

0.012

(Shi, Gerster et al.
2011)

miRNA 320 0.051

downregulation

0.038

oncogenic role in breast cancer,controls cell
proliferation,
clonogenicity,
migration,
invasion, tamoxifen resistance, tumor growth,
and micro vessel density
oncogenic role, cell proliferation, detected in
highly proliferative coloin crypts in CRC

miRNA 34a 0.019

downregulation

0.008

(Schepeler, Reinert et
al. 2008)

p53 dependent tumor suppressor,
(Munekazu
targets CDK4/6, E2F5, BcL2, SIRT1 (negative Yamakuchi*†
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June

regulator of apoptosis under stress conditions)

25, 2008)

miRNA 378 0.031

downregulation

0.031

oncogenic, promotes cell survival, tumor (Lee, Deng et al.
growth, and angiogenesis by targeting SuFu 2007)
and Fus-1 expression

miRNA 708 0.004

downregulation

0.009

tumor suppressor role, induces apoptosis and (Saini, Yamamura et
suppresses tumorigenicity in renal cancer cells al. 2011)

0.039

downregulation

0.035

inhibits proliferation of human prostate cancer (Dong, Meng et al.
cells in vitro and in vivo by targeting E2F2 2010)
and CCND2

miRNA 92a 0.032

downregulation

0.037

biomarker for detection of leukemia, controls
angiogenesis

miRNA7a
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(Tanaka, Oikawa et
al. 2009),(Angelika
Bonauer 2009)

Differential expression of miRNA in Zk-Ob compared to Zk-Ln rat colon
As part of specific aim 3, the purpose of this study was to find out if obesity alters
the miRNA expression levels when compared to its lean control. Secondly to identify
miRNAs those are affected by obesity independent of location on the colon.
In the first part of this study, the differential expression of miRNA in the proximal
colon of Zk-Ob compared to proximal colon of Zk-Ln was studied. It was found that
compared to Zk-Ln proximal colon, the Zk-Ob proximal colon showed downregulation of most the miRNAs, though majorities were not statistically significant.
The miRNAs that were significantly down-regulated in Zk-Ob proximal colon
compared to Zk-Ln proximal colon include miRNA132, miRNA 125a-5p, miRNA
134, miRNA 138, miRNA 15b, miRNA 16, miRNA 191, miRNA 195, miRNA
199a-5p, miRNA 223, miRNA 27a, miRNA 29a, miRNA 301a, miRNA 30c, miRNA
378, miRNA 429, miRNA 708, miRNA 7a and miRNA 92a. ( Figure 4.5) Whereas,
miRNA 181-b ( fold change =18.0851,p value=0.281) , miRNA 200c (fold
change=3.5934, p value=0.8087) , miRNA 210 (fold change=2.233, p value=0.7937)
and miRNA 222 (fold change=4.4617, Pvalue = 0.2822) were found to be upregulated in Zk-Ob proximal colon compared to lean proximal but none were
statistically significant. Interestingly, miRNA 223 which acts as tumor suppressor in
hepatocellular carcinoma was again found to be down-regulated in Zk-Ob proximal
colon compared to Zk-Ln proximal. (Table 4.4)
In the other part of the study, the differential expression of miRNA in distal colon of
Zk-Ob versus distal colon of Zk -Ln rats was studied. Here, most of the miRNAs are
up-regulated in Zk-Ob distal colon compared to Zk-Ln distal. The miRNAs that show
significant up-regulation include- miRNA 142-5P, miRNA 146b, miRNA 150,
miRNA 218, miRNA 223, miRNA 29b and miRNA 9. (Figure 4.6) All the other
miRNAs that show up-regulation in Zk-Ln distal colon in comparison to Zk-Ln distal
do not show statistical significance. Very few miRNA like miRNA let -7a, miRNA
103, miRNA 29a , show down-regulation but they are statistically insignificant.
miRNA 223, shows significant up-regulation in distal region of Zk Ob rat compared
to it lean counterpart.(Table 4.5)
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Looking at the two study groups, it is clearly evident that obesity does alter miRNA
expression levels when compared to control lean group. What is interesting to note
here is that obesity also seems to have a region specific effect on the colon which
reconfirms the fact that distal and proximal colon are distinct regions of the colon.
miRNAs that are up-regulated in proximal region of obese colon compared to lean
are down-regulated in distal region. For eg- miRNA 223 is up-regulated in Zk-Ob
proximal colon compared to its lean counterpart. However it is significantly downregulated in distal colon of Zk Ob rats compared to distal colon of Zk-Ln. There are
few other miRNAs eg- miRNA134, miRNA 199-5p and miRNA 708 that showed a
similar trend but were not statistically significant. (not included in result) This
reiterates the fact that proximal and distal colon indeed have distinct miRNA
expression profile and falls in place with the existing theory of colon having two
biologically distinct parts called proximal(right) and distal(left) colon. Secondly,
obesity plays a major role in regulating miRNA expression in region specific
manner.
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Figure 4.5 Differential expression of miRNAs in Zk-Ob proximal colonic mucosa
versus Zk-Ln proximal colonic mucosa. miRNA abundance in the samples was
normalized using miRNA 4.5s_V1 as endogenous control.The abundance of each of
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ob proximal
colonic mucosa compared to Zk-Ln proximal colonic mucosa (reference sample). Pvalues are calculated using student t-test application of DataAssist software v3.0
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Table 4.4-Significantly down-regulated miRNAs in Zk-Ob proximal colon compared to Zk-Ln proximal colon and their
function/targets

mi RNA

Fold
Direction
change
0.043
downregulation

Pvalue

Cellular function/target

0.0497

targets tumor suppressor protein rein (Shaked, Meerson et
retinoblastoma(pRb) in pancreatic al.
2009;
Park,
cancer cells, thus increasing cell Henry et al. 2011)
proliferation, potentiates cholinergic
anti-inflammatory
signaling
by
targeting acetylcholinesterase

miRNA
125a-5p

0.008

downregulation

0.024

directly targets oncogene ERBB2 in
gastric carcinoma cells, negatively
regulates cell proliferation and
metastasis, EGFR regulated tumor
suppressor, regulates inflammatory
response and lipid uptake in
macrophages/ monocytes

miRNA 138

0.027

downregulation

0.041

tumor suppressor, associated with (Mitomo, Maesawa
over-expression of human telomerase et al. 2008)
reverse transcriptase protein in human
anaplastic thyroid carcinoma cell
lines.

miRNA 15b

0.043

downregulation

0.042

oncogenic, correlated with tumor cell (Satzger, Mattern et
proliferation
and apoptosis in al. 2010)
malignant melanoma

miRNA 16

0.0137

down-

0.0433

tumor suppressor,
inhibits the growth (Takeshita,
66

miRNA 132

Reference

(Chen, Huang et al.
2009;
Nishida,
Mimori et al. 2011;
Guofu Wang 2009
October)

regulation

of metastatic prostate tumors via Patrawala
down-regulation of multiple cell-cycle 2009)
genes

et

al.

miRNA 191

0.005

downregulation

0.031

oncogene
that
promotes
cell
proliferation and inhibits apoptosis in
hepatocarcinoma, targets MDM4
which down-regulates p53

miRNA 195

0.003

downregulation

0.017

tumor suppressor promotes apoptosis (Liu, Chen et al.
and suppresses tumorigenicity of 2010)
human colorectal cancer cells

miRNA
199-5p

0.017

downregulation

0.010

targets hypoxia inducible factor-α in
hepatocellular carcinoma, discoidin
domain receptor-1 (DDR1) tyrosine
kinase, involved in cell invasionrelated signaling pathway is targeted
by miRNA 199-5p, targets HES
which negatively regulates cell
proliferation

(Livia Garzia 2009;
Qingli Shen1 2010;
Wang, Song et al.
2011)

miRNA 223

0.022

downregulation

0.022

targets starthmin1(oncoprotein) in
hepatocarcinoma
cells,promotes
gastric cancer invasion and metastasis
by targeting tumor suppressor
EPB41L3,negatively correlated with
oncogene c-myc, targets tumor
suppressor FBW7, that targets
oncoproteins like cyclin E, c-myc for
degradation,
induces
GLUT4
expression

(Wong, Lung et al.
2008; Lu, Buchan et
al.
2010;
Xu,
Sengupta et al. 2010;
Li, Zhang et al.
2011; Zhao WY
2011 Feb)
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(Elyakim, Sitbon et
al.
2010;
Wynendaele,
Böhnke et al. 2010)

miRNA 27a

0.043

downregulation

0.022

regulates basal transcription by (Portal 2011)
targeting the p44 subunit of general
transcription factor IIH that display
activities involved in transcription and
DNA repair processes.

miRNA 29a

0.139

downregulation

0.035

tumor suppressor, regulates
expression of numerous proteins
reduces
the
invasiveness
proliferation of human carcinoma
lines

miRNA
301a

0.027

downregulation

0.011

oncogenic
role
in
breast (Shi, Gerster et al.
cancer,controls cell proliferation, 2011)
clonogenicity, migration, invasion,
tamoxifen resistance, tumor growth,
and microvessel density

miRNA 30c

0.044

downregulation

0.010

independent predictor of clinical (Antony
benefit of endocrine therapy in 2004)
advanced estrogen receptor positive
breast cancer

miRNA 378

0.017

downregulation

0.025

oncogenic, promotes cell survival, (Lee, Deng et al.
tumor growth, and angiogenesis by 2007)
targeting SuFu and Fus-1 expression

miRNA 429

0.055

downregulation

0.012

modulates expression of c-myc, (Sun, Wang et al.)
playes important role in pathogenesis
of gastric carcinoma
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the (Muniyappa,
and Dowling et al. 2009)
and
cell

Rodriguez

miRNA 708

0.011

downregulation

0.002

tumor suppressor role, induces (Saini, Yamamura et
apoptosis
and
suppresses al. 2011)
tumorigenicity in renal cancer cells

miRNA 7a

0.047

downregulation

0.03

inhibits Proliferation of Human (Dong, Meng et al.
Prostate Cancer Cells in vitro and in 2010)
vivo by targeting E2F2 and CCND2

miRNA 92a

0.088

downregulation

0.04

MYCN-regulated miRNA-92 inhibits (Haug, Henriksen et
secretion of the tumor suppressor al. 2011)
DICKKOPF-3
(DKK3)
in
neuroblastomas
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Figure 4.6 Differential expressions of miRNAs in Zk-Ob distal colonic mucosa
versus Zk-Ln distal colonic mucosa. miRNA abundance in the samples was
normalized using miRNA 4.5s_V1 as endogenous control.The abundance of each of
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ob distal
colonic mucosa compared to Zk-Ln distal colonic mucosa (reference sample). Pvalues are calculated using student t-test application of DataAssist software v3.0
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Table 4.5- Significantly up-regulated miRNAs in Zk-Ob distal colon compared to Zk-Ln distal colon
mi RNA

Fold
change
23.12

Direction Adjusted
Cellular function/target
Reference
P value
upregulates target genes in several (Zhang, Yan et al. 2011)
regulation 0.005
oncogenic signal pathways, such as TP53,
MAPK, Wnt and vascular endothelial
growth factor.

miRNA
146b

9.84

upregulation 0.021

supresses NF-κB activity in breats cancer (Bhaumik, Scott et al.
cells,expressed in response to rising 2008; Dipa Bhaumik1
inflammatory cytokine levels as part of 2009)
negative feed back loop that restrains
excessive senescence associated secretory
phenotype.

miRNA 150

21.64

upregulation 0.018

tumor suppressor in malignant lymphoma, (Watanabe, Tagawa et al.
increases the incidence of apoptosis and 2011)
reduced cell proliferation, directly
downregulated expression of DKC1 and
AKT2, reduced levels of phosphorylated
AKTser473/4 and increased levels of tumor
suppressors such as Bim and p53.

miRNA 218

25.78

upregulation 0.013

Targets EGFR that regulates NF-κB
activity and is associated with apoptotic
response, tumor suppressor activity in
lung squamous cell carcinoma, targets
mTOR

miRNA
142-5p
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(Davidson, Larsen et al.
2010; Gao, Zhang et al.
2010; Uesugi, Kozaki et
al. 2011)

miRNA 223

20.65

upregulation 0.029

Targets starthmin1 (oncoprotein) in
hepato carcinoma cells, promotes gastric
cancer invasion and metastasis by
targeting tumor suppressor EPB41L3,
negatively correlated with oncogene cmyc, targets tumor suppressor FBW7, that
targets oncoproteins like cyclin E, c-MYC
for
degradation,
induces
GLUT4
expression

miRNA 29b

2.45

0.029
upregulation

miRNA 9

26.29

0.043
upregulation

Induces global DNA hypomethylation by (Garzon, Liu et al. 2009)
directly targeting DNMT1
(Mikihito Shibata1 2
March 2011),(Almeida,
Regulates Neurogenesis in Mouse Telen Reis et al. 2010)
cephalon
by
Targeting
Multiple
Transcription
Factors
E-cadherin
(encoded by CDH1) is a direct target of
miR-9.
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(Wong, Lung et al. 2008;
Lu, Buchan et al. 2010;
Xu, Sengupta et al. 2010;
Li, Zhang et al. 2011;
Zhao WY 2011 Feb)

Discussion
The blood plasma results indicate elevated levels of inflammatory cytokines like IL1α, IL-6, chemokines like MCP and cellular adhesion molecules like ICAM and Eselectin, in Zk-Ob compared to Zk-Ln. Obesity is a patho-physiological condition
that shows heightened inflammatory activity. Early feature of inflammation is the
release of chemokines like MCP. These factors increase the expression of interstitial
and vascular cellular adhesion molecules like ICAM and E-selectin that attracts
monocytes and immune cells. Chemokines like MCP also induce the proliferation
and pro-inflammatory gene activation producing cytokines like IL-1α, IL-6, IL-18
etc. Other factors that stimulate gene expression of pro-inflammatory cytokines in
obese state are RONS, oxidized lipids, free fatty acids.
Optimising method of miRNA isolation, detection and quantification using Zucker
rat tissue was the first aim which was achieved using Zk-Ob and Zk- Ln liver tissue.
The study showed that several miRNAs were differentially expressed in Zk-Ob liver
compared to Zk-Ln (control) liver. Out of these, 20 miRNAs were significantly upregulated, prominent among those were miRNA 137, miRNA 183, miRNA 199-3p,
miRNA 199-5p, miRNA 200c, miRNA 218, miRNA 223 and miRNA 429. miRNA
137 is known to be highly expressed in chronically inflammed model of colon
cancer. (Necela, Carr et al. 2011) Target prediction and pathway analysis suggests
that this miRNAs regulates signaling pathways related to MAPK, PI3K, WNT, and
TGF-β, all of which are known to be involved in transformation. In hepatocarcinoma cells (HCC), miRNA 183, inhibits apoptosis by targeting programmed cell
death 4 protein (PDCD4) .(Jipeng Li 2010) miRNA 199-3p target mTOR and c-Met
in HCC.(Fornari, Milazzo et al. 2010) miRNA 199-5p targets discoidin domain
receptor1 in HCC.(Qingli Shen1 2010) Similarly miRNA 200c, miRNA 218, miRNA
223 and miRNA 429 have roles either as oncogenes or tumor suppressor or pathways
related to inflammation, apoptosis, cell growth, cell cycle etc.(Table 4.6) It seems
that obesity has a profound effect on the expression levels of these miRNAs. The
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underlying factors of obesity that might be regulating the expression of these
miRNAs remains to be seen.
The primary objective of second and third aim was to use miRNA as a molecular tool
to understand the regional differences in the colon under control and obese
conditions. The findings of the present study demonstrated that both the anatomical
regions of the colonic tissue as well as the physiological state of the animal
influenced the miRNA expression pattern. However, obesity seems to be the
dominating factor that influences the expression of miRNA in the two regions of the
colon. Indeed, a selected group of miRNAs showed significant differential
expression in proximal versus distal colon in both control (lean) as well as obese
group. However, we were unable to identify common miRNAs that showed similar
expression pattern in both the groups. Hence, we can conclude that though proximal
and distal colonic regions show differential expression of miRNAs in the individual
groups which coincides with the concept of these two regions of colon being
biologically separate organs, we cannot say the same when comparing one genotype
with another. On the other hand, obesity was found to have a profound effect on the
expression pattern of miRNAs in proximal and distal colon. The miRNA that stood
out in the study, as being regulated differentially in proximal and distal colon by
obesity factor, is miRNA 223. This miRNA was significantly up-regulated in the
proximal colon compared to distal in the control lean group. However, in obese
group, the same miRNA was down-regulated significantly in the proximal colon
compared to distal. Obesity seems to be influencing the expression of miRNA 223 in
such a way that it is highly expressed in the distal colonic region and has a very low
expression in proximal colon. There were several other miRNAs that seemed to be
influenced by obesity such that expression is drastically altered in the two regions of
the colon. However, they were not significant and hence not included. It would be
interesting to find out the factors associated with obesity that could be playing a role
here. Pro-inflammatory cytokines like IL-6, IL-1α, chemokines like MCP and
adhesion molecules like ICAM, E-selectin which were found elevated in obese group
when compared to lean (control) might be involved in regulation of miRNA
expression in site specific manner.
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There were 16 miRNAs shortlisted from all the analysis that was found to be
significantly up or down-regulated. (Table 4.6) Target prediction of these miRNAs,
using a combination of bioinformatics tool like miRanda, PicTar and Target Scan,
indicated their role in inflammation, cell proliferation, cell growth, apoptosis, DNA
damage and repair etc . These findings suggest that the molecular make up of the
tissue is profoundly affected by genotype and tissue biology.
miRNA 218 was found to be influenced by obesity so that its expression is upregulated significantly in the distal colon under obese conditions. It has been
experimentally proven that miRNA 218 has tumor suppressor activity in squamous
cell carcinoma, where it may directly or indirectly target MYC and SRC oncogenes.
(Davidson, Larsen et al. 2010) Interestingly, one of the several targets of miRNA
218, as found by miRanda bioinformatics tool was CDC 27 (cell division cycle
protein 27 homologue) . This protein is a part of the anaphase promoting complex
subunit3, a cell cycle-regulated E3 ubiquitin ligase that controls progression through
mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating
ubiquitination and subsequent degradation of target proteins. miRNA 218 binds to
the 3’UTR of this cell cycle protein, hence has an oncogenic role.
miRNA 223 was down-regulated in the proximal region of the colon under obese
conditions. In liver the expression was 46 fold high in the obese group compared to
control lean liver. miRNA 223 is known to have tumorigenic functions in hepatocarcinoma. Overexpression of miRNA 223 in mouse embryonic fibroblasts cell lines
lead to reduced expression of tumor suppressor FBW7, which targets oncogenes like
cMYC and cyclinE for ubiquitination and degradation.(Xu, Sengupta et al. 2010) It
has been found to be negatively correlated with cMYC oncogene in hepatocarcinoma (Zhao WY 2011 Feb). Interestingly, p53 was also found to be one of the
targets of miRNA 223, though not experimentally validated. (Source: Uniprot/
SWISSPROT ; Acc : P10361). Other predicted target genes identified by more than
one algorithm were myotrophin (Mtpn), Ras related protein rab-10 (Rab10), nuclear
factor IA (NfIa), myocyte enhancer factor 2c (Mef2c), and insulin-like growth factor
1receptor (Igf1r). Glut4 could be a direct targetof miR-223 across species, possible
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through the interaction of multiple target sites. Over-expression of miR-223 in vitro
inhibited insulin-stimulated Akt and GSK3b phosphorylation in cardiomyocytes.
miRNA 223 is also known to induce the expression of GLUT4 (Glucose transporter4)
and increases the basal glucose uptake in cardiomycetes.(Lu, Buchan et al. 2010)
miRNA 199-5p showed down-regulation in the proximal colon compared to distal
colon of both lean and obese group. However, liver showed significant up-regulation
(16 fold) in obese rat compared to control lean rat. This might be because of
independent mechanisms of miRNA regulation in liver and colon. In hepatocarcinoma (HCC) tumors, the under expression of miRNA 199-5p, which happens
via hypoxia inducible factor (Hif1α) , is inversely correlated with survival and
directly with malignancy of HCC.
miRNA 125-5p showed similar trend. i.e down-regulation in proximal region of the
colon under obese condition and up-regulation in obese liver. miRNA 125-5p is
known to modulate inflammatory response and lipid uptake in macrophages and
monocytes. (Chen, Huang et al. 2009). miRNA 125-5p directly targets oxysterol
binding protein related protein 9(ORBP-9) , which is a cholesterol transfer protein
that regulates golgi-structure and function.(Ridgway 2009 March 1) ORBP9
maintains the integrity of the early secretory pathway by mediating transport of
sterols between the ER and trans-Golgi/TGN. Down-regulation of ORBP-9 by
miRNA 125-5p, causes Golgi fragmentation, inhibition of vesicular somatitus virus
glycoprotein transport from the ER and accumulation of cholesterol in endosomes
/lysosomes.(Ridgway 2009 March 1)
miRNA 132 also shows significant down-regulation in proximal colon compared to
distal colon under obese condition. It is highly expressed in liver. In the brain,
miRNA 132 directly targets Acetylcholinesterase (AChE) attenuating inflammation
by reducing AChE amounts.(Shaked, Meerson et al. 2009). In pancreatic
adenocarcinoma, miRNA 132 acts as oncogene by targeting tumor suppressor
Retinoblastoma protein (pRb).
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miRNA 183 showed significant differential regulation only in the obese group. In
Zk-Ob rats, it was down-regulated 23 fold times in proximal colon compared to
distal colon. In the liver tissue, the expression was 7 fold more in the obese group
compared to the lean group. miRNA 183 is overexpressed in several cancer types egcolon cancer, synovial sarcoma . It targets the tumor suppressor EGR1 and
PTEN.(Sarver, Li et al. 2010).
miRNA 191 shows significant down-regulation in proximal colon compared to distal
colon in the obese group. It is up-regulated in the obese liver (185 fold) compared to
lean liver .miRNA 191 targets MDM4 which down-regulates p53.(Wynendaele,
Böhnke et al. 2010) In hepato-carcinoma, miRNA 191 has an oncogenic role where
they increase cell proliferation and inhibits apoptosis. (Elyakim, Sitbon et al. 2010)
miRNA 191 does show a region specific difference in expression and is induced
under obese conditions which might the factor regulation its differential expression.
miRNA 301a showed very high expression in distal colon compared to proximal
colon under obese conditions. miRNA 378 enhances cell survival, tumor growth and
angiogenesis by targeting two tumor suppressors Sufu and Fus-1 (Lee, Deng et al.
2007) in a normal cell. It has been reported that over-expression of miRNA 378
during adipogenesis increases triacylgylcerol accumulation due to increased de novo
lipogenesis.

Interestingly, miR-378/378∗ is located within the peroxisome

proliferator-activated receptor gamma(PPAR-γ) coactivator-1 beta gene and is
transcribed during adipocyte differentiation .
Other miRNAs like miRNA 708, 92a, 15b and 21 expressions were also
significantly altered in the two different regions of the colon under obese conditions.
Some of them were exclusively expressed in colon and not liver. miRNA 708
induces apoptosis . In renal cancer it targets the regulators of E-cadherin such as
ZEB2 and BMI1, suppresses epithelial to mesenchymal transition(EMT) and hence
acts as a tumor suppressor.(Saini, Yamamura et al. 2011). In liver miRNA 92a did
not show any significant differential regulation in obese versus lean. Among the
miRNAs that were expressed at lower levels in proximal colon under obese
conditions, miRNA 21 stands out as an important miRNA . This miRNA has been
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extensively studied as a major player in inflammation and inflammation related
disorders including cancer. Hence its high expression in liver was well expected.
However its downregulation in proximal colon compared to distal shows how distal
and proximal colon stand as distinct organs with independent mechanisms of gene
regulation. Pro-inflammatory cytokines like IL-6, activate STAT-3 transcription
factor, which directly binds to the promoter of miRNA21 and activates it. miRNA 21
targets tumor suppressors like PTEN, leading to increased NF-κB activity, which
promotes cell survival and cell proliferation. (Iliopoulos, Hirsch et al. 2009) PTEN
is a tumor suppressor gene encoding a phosphatase that regulates cell cycle, Akt and
p53 activity. Tropomyosin 1 (TPM1) and programmed cell death 4 (PDCD4) are
other tumor suppressors targeted by miRNA21. miRNA 21 expression has been
correlated as a part of inflammatory response in many cancers including colon
cancer. IL-6 is thought to drive the expression of miRNA 21 in a STAT dependent
manner. (Lu, Munitz et al. 2009) There is also a predicted binding site for miR-21 in
the 3′ untranslated region(3’UTR) of IL-12a as indicated by Targetscan and
miRanda. Aberrant over-expression of miRNA 21 has been attributed to activated
EGFR signaling. (Seike, Goto et al. 2009) miRNA 21 has strong connection with
inflammation and hence its up-regulation in obese conditions both in liver as well as
colon, is expected. However, the role of obesity associated inflammation in
regulating the differential expression of miRNA 21 in colon is not clear at this point.
In addition to the miRNAs discussed in the preceeding section a number of miRNAs
such as 29, 29b, 30c and 34a were also found altered in different colonic regions
under obese conditions.
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Table 4.6- Summary of miRNAs showing significant differential regulation in Zk-Ob versus Zk-Ln and proximal
versus distal colonic mucosa
micro
RNA
miRNA 218

Physiolo
gical
state
Lean

obese
obese

miRNA 223

Colon/liv
er

Reference
sample

Fold
change/direction

proximal
colon

distal colon

130 X upregulation

distal
colon
liver

lean distal

25 X up-regulation

lean liver

8X up-regulation

Lean

proximal
colon

distal colon

41 X up-regulation

obese

proximal
colon
proximal
colon
distal
colon
liver

distal colon
lean
proximal
lean distal

42 X downregulation
46 X downregulation
34 X up-regulation

lean liver

8 X up-regulation

obese
obese
obese
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Biological function

tumor suppressor activity in squamous
cell carcinoma, targets EGFR, targets
mTOR

acts as tumor suppressor by targeting
stathmin1 oncoprotein, targets tumor
suppressor
EPB4IL3,
negatively
correlated with oncogene c-myc, targets
tumor suppressor FBW7, which targets
oncogenes like cMYC and cyclin E for
ubiquitination and degradation, induces
GLUT4
(
glucose
transporter4)
expression

miRNA
199-5p

obese

proximal
colon

distal colon

312 X fold downregulation

obese

proximal
colon
liver

lean
proximal
lean liver

57 X downregulation
16 X up-regulation

obese

proximal
colon

distal colon

208 X downregulation

obese

proximal
colon
liver

lean
proximal
lean liver

116 X
downregulation
6 X upregulation

Obese

proximal
colon

distal colon

102 X downregulation

Obese

proximal
colon
liver

lean
proximal
lean liver

23 X downregulation
7 X up-regulation

proximal
colon
liver

distal colon

oncogene, promotes cell migration

lean liver

30 X downregulation
12 X up-regulation

obese

proximal
colon

lean
proximal

185 X downregulation

oncogene, promotes cell proliferation and
inhibits apoptosis, tumor suppressor
targets MDM4

obese

liver

lean liver

4 X up-regulation

obese
miRNA
125a-5p

Obese
miRNA 132

obese
miRNA 183

obese
obese

mi RNA
191
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tumor suppressor in hepato-cellular
carcinoma, oncogenic in medulloblastoma tumor cells

targets oncogene ERBB2 in gastric
carcinoma cells, regulates inflammatory
response
and
lipid
uptake
in
monocytes/macrophages.

Oncogene, targets pRb tumor suppressor
in
pancreatic
cancer,
Potentiates
Cholinergic Anti-inflammatory Signaling
by targeting acetylcholinesterase

mi RNA
301a

obese
obese

mi RNA
378

obese
obese

mi RNA
708

miRNA 92a

proximal
colon
proximal
colon

distal colon
lean
proximal
colon
distal colon
lean
proximal

196 X downregulation
37 X
downregulation

oncogenic role in breast cancer

25 X downregulation
40 X downregulation

oncogenic , promotes cell survival and
tumor growth

tumor suppressor, induces apoptosis

obese

proximal
colon

distal colon

104 X downregulation

obese

proximal

lean
proximal

526 X downregulated

obese

proximal
colon
proximal
colon

distal colon

tumor suppressor, controls angiogenesis
in leukemia

lean
proximal

27 X downregulation
25 X downregulated

proximal
colon
Liver

lean
proximal
lean liver

24 X downregulated
7 X up-regulation

oncogenic role in malignant melanoma

proximal
colon
liver

distal colon

oncogenic role, targets PTEN

lean liver

20 X downregulation
5 X up-regulation

lean distal

2 X up-regulation

both oncogenic and tumor suppressor
rolerole, targets DNMT

distal colon

10 X up-regulation

obese

miRNA 15b obese
obese
miRNA 21

proximal
colon
proximal
colon

obese
obese

miRNA 29b obese
lean

distal
colon
proximal
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colon
miRNA 30c

lean
obese

miRNA 34a

proximal
colon
proximal
colon

distal colon

16 X up-regulation

lean
proximal

99 X downregulation

obese

proximal
colon

distal colon

123 X downregulation

obese

liver

lean liver

3 X up-regulation
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tumor suppressor

p53 dependent tumor suppressor,
targets CDK4/6, E2F5, BcL2, SIRT1
(negative regulator of apoptosis under
stress conditions)

CHAPTER 5
CONCLUSION AND RECOMMENDATION

When one looks at an overall trend it is apparent that miRNAs are expressed in a
tissue specific manner. Differential miRNA expression in distal and proximal colon
of both lean and obese group strengthens the molecular evidences supporting the idea
of existence of proximal and distal colon as separate organs. However, obesity seems
to be significantly altering the pattern of miRNA expression in these two regions
when compared with control lean group. Several miRNAs that showed up-regulation
in distal colon compared to proximal colon in control lean group, show completely
reverse trend in the obese group. The results obtained demonstrated that obesity
seem to profoundly affect the expression levels of several miRNAs. Moreover, the
findings also demonstrated that distinct regional differences exist in the colon with
respect to expression levels of miRNA. The miRNAs that showed significant
changes are oncogenic as well as tumor suppressors in cancerous cells and also have
role in apoptosis, cell growth and differentiation. The findings of the present research
supports the hypothesis that selected miRNAs could serve to distinguish molecular
differences among tissue types and that colonic regions expressing different miRNAs
expression pattern and levels further confirm that these sites are

biologically

different entities. These differences may in part be responsible for emergence and
selection of preneoplastic lesions with different mutations and growth rates.
However, physiological state such as obesity in this case, cannot be overlooked
especially when it seems to be altering the miRNA expression pattern in the different
regions of the colon, in such a significant manner.
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Summary and Future research
The findings of the present research have provided a strong foundation to further explore
the role of miRNAs in colon carcinogenesis. Whether some of these miRNAs are
secreted in the blood to detect the presence of an early disease state remains to be seen.
Role of selected miRNAs particularly the miRNAs involved in pathways like
inflammation, oxidative stress, cholesterol biosynthesis, DNA damage, repair and
apoptosis will be of interest. In this study, we have focused on the expression of miRNA
in distal versus proximal colon in obese model. In our study we could not identify
common miRNAs which could serve as biomarkers for distal and proximal colon, in both
lean and obese group. However, we conclude that proximal and distal colon show distinct
pattern of miRNA expression which depends on the host’s physiology. Our results
indicate that miRNA expression is indeed influenced by obesity and also show site
specific variation in colon. In future, the connection between obesity and colonic region
specific miRNA expression needs to be validated. Also, it would be interesting to see if
the pattern of miRNA expression is the same in the different stages of colon cancer such
as ACF, adenoma and adenocarcinoma. The study of underlying mechanisms connecting
obesity with miRNA expression in proximal versus distal colonic tumor will give a
deeper insight into the complexity of colon carcinogenesis.
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APPENDICES

APPENDIX A

A.1

Blood Plasma analysis of Zk-Ob and Zk-ln rats

Commercially available assay using Luminex liquid antibody bead array technology was
used to measure a panel of cytokines, inflammatory biomarkers and adhesion molecule
endpoints in plasma, e.g intercellular adhesion molecules(ICAM), E-selectin, monocyte
chemoattractant protein ( MCP ), IL-1α, IL-6 according to manufacturer’s instructions.
(Lincoplex, Millipore Bioplex and BioRad). Values are mean ± SE, n=4 samples per
group.

A.2

Results

Figure 1- Plasma levels of ICAM-1 in Zk-Ob and Zk-Ln (control)
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Figure 2- Plasma levels of E-selectin in Zk-Ob and Zk-Ln (control)

Figure 3- Plasma levels of MCP-1 in Zk-Ob and Zk-Ln(control)

86

Figure 4- Plasma levels of IL-1α in Zk-Ob and Zk-Ln(control)

Figure 5 – Plasma levels of IL-6 in Zk-Ob and Zk-Ln (control)
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APPENDIX B

B.1 Reaction Components for cDNA synthesis for miRNA quantification

Template miRNA

10-20 ng

miScript RT buffer(5X)*

2µl

miScriptReverse Transcriptase

1µl

Mix
RNase free water

variable

Total reaction volume

10µl

B.2 Real time PCR for miRNA quantification
2x Quanti Tect SYBR Green PCR

10µl

Master Mix
10x mi Script Universal Primer

2µl

10x mi Script Primer Assay

2µl

Template cDNA

3 ng/reaction

RNase free water

variable

Total volume

20 µl
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B.3 Cycling conditions for real-time PCR for miRNA quantification
Step

Time

Temperature

Specifications

PCR initial activation step

15 min

95°C

HotStarTaq DNA Polymerase is
activated by this heating step.

15 sec

94°C

30 sec

55°C

34 sec

70°C

3-step cycling:
Denaturation
Annealing
Extension
Cycle number

Fluorescence data collection.

40 cycles

B.4 Components for cDNA synthesis for miRNA array
For each reaction, the following components were added in a sterile PCR tube
Small RNA – 50-400 ng of mi RNA enriched fraction
5x miRNA RT Buffer 2 - 2.0 µl
RT Enzyme Mix - 1.0 µl
Nucleotide Mix - 1.0 µl
RT primer + ERC mix – 1.0 µl
RNase-free H2O to a final volume of 10.0 µl

B.5 Components for real time PCR step in array experiment

2X RT2 SYBR Green qPCR Mastermix –1275 µL
Diluted first strand reaction-100 µL
RNase free H2O- 1175 Μl
Total volume- 2550 µL
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B.6 Cycling conditions for real time PCR for array experiment

Cycles

Duration

Temperature

1

10 minutes

95°C

15 seconds
40 seconds
32 seconds

95°C
60°C
72°C

40

B.7 RT2 miRNA array layout
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